U.S. patent application number 12/075070 was filed with the patent office on 2008-09-11 for metalloprotease inhibitors containing a heterocyclic moiety.
Invention is credited to Carine Chevrier, Brian M. Gallagher, Christian Gege, Arthur Taveras.
Application Number | 20080221095 12/075070 |
Document ID | / |
Family ID | 39551667 |
Filed Date | 2008-09-11 |
United States Patent
Application |
20080221095 |
Kind Code |
A1 |
Gege; Christian ; et
al. |
September 11, 2008 |
Metalloprotease inhibitors containing a heterocyclic moiety
Abstract
The present invention relates generally to pharmaceutical agents
containing a heterocyclic moiety, and in particular, to
heterocyclic metalloprotease inhibiting compounds. More
particularly, the present invention provides a new class of
heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a
squaramide or benzoxazinone moiety, that exhibit an increased
potency and selectivity in relation to currently known MMP-13,
MMP-8 and MMP-3 inhibitors.
Inventors: |
Gege; Christian; (Mauer,
DE) ; Chevrier; Carine; (Munchen, DE) ;
Gallagher; Brian M.; (Merrimac, MA) ; Taveras;
Arthur; (Southborough, MA) |
Correspondence
Address: |
AMGEN INC.
MAIL STOP 28-2-C, ONE AMGEN CENTER DRIVE
THOUSAND OAKS
CA
91320-1799
US
|
Family ID: |
39551667 |
Appl. No.: |
12/075070 |
Filed: |
March 7, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60905565 |
Mar 7, 2007 |
|
|
|
Current U.S.
Class: |
514/230.5 ;
514/269; 544/105; 544/319 |
Current CPC
Class: |
A61P 13/00 20180101;
A61P 13/12 20180101; A61P 39/06 20180101; A61P 1/02 20180101; A61P
19/10 20180101; A61P 1/18 20180101; A61P 3/10 20180101; A61P 9/00
20180101; A61P 11/00 20180101; A61P 25/04 20180101; A61P 29/02
20180101; A61P 31/18 20180101; A61P 35/04 20180101; A61P 37/06
20180101; A61P 25/28 20180101; A61P 9/12 20180101; A61P 11/06
20180101; A61P 19/02 20180101; A61P 31/12 20180101; A61P 11/02
20180101; A61P 27/02 20180101; C07D 519/00 20130101; A61P 17/10
20180101; A61P 31/04 20180101; A61P 1/04 20180101; A61P 19/06
20180101; A61P 21/00 20180101; A61P 37/08 20180101; A61P 11/14
20180101; A61P 27/06 20180101; A61P 33/06 20180101; C07D 498/02
20130101; A61P 25/00 20180101; A61P 7/02 20180101; A61P 17/04
20180101; A61P 1/16 20180101; A61P 15/00 20180101; A61P 29/00
20180101; A61P 13/02 20180101; A61P 17/06 20180101; A61P 17/16
20180101; A61P 25/16 20180101; A61P 19/00 20180101; A61P 25/18
20180101; A61P 27/16 20180101; A61P 35/00 20180101; A61P 17/00
20180101; A61P 17/02 20180101; A61P 43/00 20180101; A61P 9/14
20180101; A61P 7/00 20180101; A61P 15/06 20180101; A61P 19/08
20180101; A61P 9/10 20180101; C07D 487/02 20130101 |
Class at
Publication: |
514/230.5 ;
544/319; 514/269; 544/105 |
International
Class: |
A61K 31/538 20060101
A61K031/538; C07D 239/36 20060101 C07D239/36; A61K 31/513 20060101
A61K031/513; A61P 19/02 20060101 A61P019/02; C07D 413/12 20060101
C07D413/12 |
Claims
1. A compound having Formula (I): ##STR00385## wherein: R.sup.4 in
each occurrence is independently selected from R.sup.10, hydrogen,
alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo,
haloalkyl, CF.sub.3, (C.sub.0-C.sub.6)-alkyl-COR.sup.10,
(C.sub.0-C.sub.6)-alkyl-OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NO.sub.2, (C.sub.0-C.sub.6)-alkyl-CN,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.yOR.sup.10,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.yNR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10CONR.sup.11SO.sub.2R.sup.30,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.xR.sup.10,
(C.sub.0-C.sub.6)-alkyl-OC(O)R.sup.10,
(C.sub.0-C.sub.6)-alkyl-OC(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(.dbd.NR.sup.10)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10C(.dbd.NR.sup.11)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10SO.sub.2R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)--NR.sup.11--CN,
O--(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
S(O).sub.x--(C.sub.0-C.sub.6)-alkyl-C(O)OR.sup.10,
S(O).sub.x--(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10--(C.sub.0-C.sub.6)-alkyl-NR.sup.10R-
.sup.11, (C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)R.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)--NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--S(O).sub.yNR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--S(O).sub.yR.sup.10,
O--(C.sub.0-C.sub.6)-alkyl-aryl and
O--(C.sub.0-C.sub.6)-alkyl-heteroaryl, wherein each R.sup.4 group
is optionally substituted one or more times, or wherein each
R.sup.4 group is optionally substituted by one or more R.sup.14
groups; R.sup.8 is selected from R.sup.10 or optionally R.sup.8 and
X.sup.1 when taken together with the nitrogen and sp.sup.2-carbon
atom to which they are attached complete a 5- to 8-membered
unsaturated or partially unsaturated heterocycle optionally
containing additional heteroatoms selected from O, S(O).sub.x, N or
NR.sup.50 and which is optionally substituted one or more times;
R.sup.9 in each occurrence is independently selected from R.sup.10,
hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
halo, CHF.sub.2, CF.sub.3, OR.sup.10, SR.sup.10, COOR.sup.10,
CH(CH.sub.3)CO.sub.2H, (C.sub.0-C.sub.6)-alkyl-COR.sup.10,
(C.sub.0-C.sub.6)-alkyl-OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NO.sub.2, (C.sub.0-C.sub.6)-alkyl-CN,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.yOR.sup.10,
(C.sub.0-C.sub.6)-alkyl-P(O).sub.2OH,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.yNR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10CONR.sup.11SO.sub.2R.sup.30,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.xR.sup.10,
(C.sub.0-C.sub.6)-alkyl-OC(O)R.sup.10,
(C.sub.0-C.sub.6)-alkyl-OC(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(.dbd.NR.sup.10)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10C(.dbd.NR.sup.11)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10C(.dbd.N--CN)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(.dbd.N--CN)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10C(.dbd.N--NO.sub.2)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(.circleincircle.N--NO.sub.2)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10SO.sub.2R.sup.11,
C(O)NR.sup.10--(C.sub.0-C.sub.6)-alkyl-heteroaryl,
C(O)NR.sup.10--(C.sub.0-C.sub.6)-alkyl-aryl,
S(O).sub.2NR.sup.10--(C.sub.0-C.sub.6)-alkyl-aryl,
S(O).sub.2NR.sup.10--(C.sub.0-C.sub.6)-alkyl-heteroaryl,
S(O).sub.2NR.sup.10-alkyl, S(O).sub.2-(C.sub.0-C.sub.6)-alkyl-aryl,
S(O).sub.2-(C.sub.0-C.sub.6)-alkyl-heteroaryl,
(C.sub.0-C.sub.6)-alkyl-C(O)--NR.sup.11--CN,
O--(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
S(O).sub.x--(C.sub.0-C.sub.6)-alkyl-C(O)OR.sup.10,
S(O).sub.x--(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10--(C.sub.0-C.sub.6)-alkyl-NR.sup.10R-
.sup.11, (C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)R.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)--NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--S(O).sub.yNR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--S(O).sub.yR.sup.11,
O--(C.sub.0-C.sub.6)-alkyl-aryl and
O--(C.sub.0-C.sub.6)-alkyl-heteroaryl, wherein each R.sup.9 group
is optionally one or more times substituted; R.sup.10 and R.sup.11
in each occurrence are independently selected from hydrogen, alkyl,
cycloalkyl, cycloalkylalkyl, heterocycloalkyl, fluoroalkyl,
heterocycloalkylalkyl, haloalkyl, alkenyl, alkynyl, aryl,
heteroaryl, arylalkyl, heteroarylalkyl and aminoalkyl, wherein
alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, fluoroalkyl,
heterocycloalkylalkyl, alkenyl, alkynyl, aryl, heteroaryl,
arylalkyl, heteroarylalkyl and aminoalkyl are optionally
substituted one or more times, or R.sup.10 and R.sup.11 when taken
together with the nitrogen to which they are attached complete a 3-
to 8-membered ring containing carbon atoms and optionally
containing a heteroatom selected from O, S(O).sub.x, or NR.sup.50
and which is optionally substituted one or more times; R.sup.14 is
independently selected from hydrogen, alkyl, arylalkyl,
cycloalkylalkyl, heteroarylalkyl, heterocyclylalkyl and halo,
wherein alkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and
heterocyclylalkyl are optionally substituted one or more times;
R.sup.17 is selected from R.sup.9, alkenyl, alkynyl, bicycloalkyl,
heterobicycloalkyl, spiroalkyl, spiroheteroalkyl, cycloalkyl fused
aryl, heterocycloalkyl fused aryl, cycloalkyl fused heteroaryl,
heterocycloalkyl fused heteroaryl or a bicyclic or tricyclic fused
ring system, wherein at least one ring is partially saturated, and
wherein each R.sup.17 group is optionally substituted one or more
times, or wherein each R.sup.17 group is optionally substituted one
or more R.sup.9 groups; R.sup.30 is selected from alkyl and
(C.sub.0-C.sub.6)-alkyl-aryl, wherein alkyl and aryl are optionally
substituted; R.sup.50 in each occurrence is independently selected
from hydrogen, alkyl, aryl, heteroaryl, C(O)R.sup.80,
C(O)NR.sup.80R.sup.81, SO.sub.2R.sup.80 and
SO.sub.2NR.sup.80R.sup.81, wherein alkyl, aryl, and heteroaryl are
optionally substituted one or more times; R.sup.80 and R.sup.81 in
each occurrence are independently selected from hydrogen, alkyl,
cycloalkyl, cycloalkylalkyl, heterocycloalkyl, fluoroalkyl,
heterocycloalkylalkyl, haloalkyl, alkenyl, alkynyl, aryl,
heteroaryl, arylalkyl, heteroarylalkyl and aminoalkyl, wherein
alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, fluoroalkyl,
heterocycloalkylalkyl, alkenyl, alkynyl, aryl, heteroaryl,
arylalkyl, heteroarylalkyl and aminoalkyl are optionally
substituted, or R.sup.80 and R.sup.81 when taken together with the
nitrogen to which they are attached complete a 3- to 8-membered
ring containing carbon atoms and optionally a heteroatom selected
from O, S(O).sub.x, NH, and N(alkyl) and which is optionally
substituted one or more times; L.sub.c is selected from a single
bond or an acyclic, straight or branched, saturated or unsaturated
hydrocarbon chain having 1 to 10 carbon atoms, optionally
containing 1 to 3 groups independently selected from --S--, --O--,
NR.sup.10--, --NR.sup.10CO--, --CONR.sup.10--, --S(O).sub.x--,
--SO.sub.2NR.sup.10--, --NR.sup.10SO.sub.2--,
NR.sup.10SO.sub.2NR.sup.10, --NR.sup.10CONR.sup.10--,
--OC(O)NR.sup.10--, --NR.sup.10C(O)O--, which replace single carbon
atoms, which in case that more than two carbon atoms are replaced
are not adjacent, and wherein the hydrocarbon chain is optionally
substituted one or more times; L.sub.d is selected from a single
bond or a straight or branched, saturated or unsaturated
hydrocarbon chain having 1 to 10 carbon atoms, optionally
containing 1 to 3 groups independently selected from --O--,
--NR.sup.10--, --S(O).sub.x--, --NR.sup.10C(X.sup.1)--,
--C(X.sup.1)NR.sup.10--, --SO.sub.2NR.sup.10--,
--NR.sup.10SO.sub.2--, --O--SO.sub.2--, --SO.sub.2--O--,
--NR.sup.10SO.sub.2NR.sup.10--, --NR.sup.10C(X.sup.1)NR.sup.10--,
--OC(X.sup.1)NR.sup.10--, --NR.sup.10C(X.sup.1)O--,
--OC(X.sup.1)--, --C(X.sup.1)O--, -Q.sup.2, --NR.sup.10-Q.sup.2,
-Q.sup.2-NR.sup.10--, --C(X.sup.1)-Q.sup.2, -Q.sup.2-C(X.sup.1)--,
--O-Q.sup.2-, --S(O).sub.x-Q.sup.2, and -Q2-S(O).sub.x-- which
replace single carbon atoms, which in case that more than two
carbon atoms are replaced are not adjacent, and wherein the
hydrocarbon chain is optionally substituted one or more times;
Q.sup.1 is a 4- to 8-membered ring selected from cycloalkyl,
heterocycloalkyl, bicycloalkyl, heterobicycloalkyl or a 5- or
6-membered ring selected from aryl and heteroaryl, wherein
cycloalkyl, heterocycloalkyl, bicycloalkyl, heterobicycloalkyl,
aryl and heteroaryl are optionally substituted one or more times by
R.sup.4 and optionally a substituent of Q.sup.1 is linked with
L.sub.d to complete a 3- to 8-membered ring containing carbon atoms
and optionally heteroatoms selected from O, S(O).sub.x, --NH, and
--N(alkyl) wherein this new ring is optionally substituted one or
more times; Q.sup.2 is independently selected from an aromatic,
partially aromatic or non-aromatic cyclic, bicyclic or multicyclic
system containing 0 to 8 heteroatoms selected from N, O and
S(O).sub.x, which is optionally substituted one or more times with
R.sup.4 and wherein the cycles are optionally spiro fused and
optionally a substituent of Q.sup.2 is linked with L.sub.d to
complete a 3- to 8-membered ring containing carbon atoms and
optionally heteroatoms selected from O, S(O).sub.x, --NH, and
--N(alkyl) wherein this new ring is optionally substituted one or
more times; X.sup.1 is independently selected from O, S, NR.sup.10,
NOR.sup.10, N--CN, NCOR.sup.10, N--NO.sub.2, and
N--SO.sub.2R.sup.10; Y is selected from O, S(O).sub.x,
CR.sup.10OR.sup.11, and NR.sup.10; Z.sup.1 is independently
selected from C, S, S.dbd.O, PR.sup.10 and P--OR.sup.10; w is
independently selected from 0 to 3; x is independently selected
from 0 to 2; y is selected from 1 and 2; and N-oxides,
pharmaceutically acceptable salts, prodrugs, formulations,
polymorphs, racemic mixtures and stereoisomers thereof.
2. The compound of claim 1, wherein the group
Q.sup.2-L.sub.c-R.sup.17 is selected from: ##STR00386##
##STR00387## ##STR00388## wherein: R.sup.5 in each occurrence is
independently selected from hydrogen, alkyl, C(O)NR.sup.10R.sup.11,
aryl, arylalkyl, SO.sub.2NR.sup.10R.sup.11 and C(O)OR.sup.10,
wherein alky, aryl and arylalkyl are optionally substituted one or
more times; E is independently selected from a bond,
CR.sup.10R.sup.11, O, NR.sup.5, S, S.dbd.O, S(.dbd.O).sub.2,
C(.dbd.O), N(R.sup.10)(C.dbd.O), (C.dbd.O)N(R.sup.10),
N(R.sup.10)S(.dbd.O).sub.2, S(.dbd.O).sub.2N(R.sup.10),
C.dbd.N--OR.sup.11, --C(R.sup.10R.sup.11)C(R.sup.10R.sup.11)--,
--CH.sub.2--W.sup.1-- and ##STR00389## Q.sup.3 is selected from an
aromatic, partially aromatic or non-aromatic cyclic, bicyclic or
multicyclic system containing 0 to 8 heteroatoms selected from N, O
and S(O).sub.x, which is optionally substituted one or more times
with R.sup.4; Q.sup.4 is selected from an aromatic, partially
aromatic or non-aromatic cyclic, bicyclic or multicyclic system
containing 0 to 8 heteroatoms selected from N, O and S(O).sub.x,
which is optionally substituted one or more times with R.sup.4; U
is independently selected from C(R.sup.5R.sup.10), NR.sup.5, O, S,
S.dbd.O and S(.dbd.O).sub.2; W.sup.1 is independently selected from
O, NR.sup.5, S, S.dbd.O, S(.dbd.O).sub.2, N(R.sup.11)(C.dbd.O),
N(R.sup.10)S(.dbd.O).sub.2 and S(.dbd.O).sub.2N(R.sup.10); and g
and h are independently selected from 0-2.
3. The compound of claim 2, wherein Q.sup.4 is selected from an
aromatic, partially aromatic or non-aromatic bicyclic or
multicyclic system containing 0 to 8 heteroatoms selected from N, O
and S(O).sub.x, which is optionally substituted one or more times
with R.sup.4.
4. The compound of claim 3 selected from: ##STR00390## wherein:
R.sup.8 is selected from R.sup.10 or optionally R.sup.8and X.sup.1
when taken together with the nitrogen and sp.sup.2-carbon atom to
which they are attached complete a 5- to 8-membered unsaturated or
partially unsaturated heterocycle optionally containing additional
heteroatoms selected from O, S(O).sub.x, N or NR.sup.50 and which
is optionally substituted one or more times; L, M and T are
independently selected from CR.sup.9 and N; X.sup.1 is
independently selected from O, S, NR.sup.10, NOR.sup.10, N--CN,
NCOR.sup.10, N--NO.sub.2, and N--SO.sub.2R.sup.10.
5. A pharmaceutical composition comprising an effective amount of a
compound according to claim 1; and a pharmaceutically-acceptable
carrier.
6. A method of treating rheumatoid arthritis, osteoarthritis or
inflammation comprising administering a therapeutically-effective
amount of a compound according to claim 1.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Application No. 60/905,565, filed Mar. 7, 2007, which is hereby
incorporated by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to a new class of heterocyclic
moiety containing pharmaceutical agents which inhibits
metalloproteases. In particular, the present invention provides a
new class of metalloprotease inhibiting compounds containing a
benzoxazinone moiety that exhibit potent inhibiting activity
towards metalloproteases, in particular towards MMP-13, MMP-3,
MMP-8, and more particulary towards MMP-13.
BACKGROUND OF THE INVENTION
[0003] Matrix metalloproteinases (MMPs) and aggrecanases (ADAMTS=a
disintegrin and metalloproteinase with thrombospondin motif) are a
family of structurally related zinc-containing enzymes that have
been reported to mediate the breakdown of connective tissue in
normal physiological processes such as embryonic development,
reproduction, and tissue remodelling. Over-expression of MMPs and
aggrecanases or an imbalance between extracellular matrix synthesis
and degradation has been suggested as factors in inflammatory,
malignant and degenerative disease processes. MMPs and aggrecanases
are, therefore, targets for therapeutic inhibitors in several
inflammatory, malignant and degenerative diseases such as
rheumatoid arthritis, osteoarthritis, osteoporosis, periodontitis,
multiple sclerosis, gingivitis, corneal epidermal and gastric
ulceration, atherosclerosis, neointimal proliferation (which leads
to restenosis and ischemic heart failure) and tumor metastasis.
[0004] The ADAMTSs are a group of proteases that are encoded in 19
ADAMTS genes in humans. The ADAMTSs are extracellular, multidomain
enzymes whose functions include collagen processing, cleavage of
the matrix proteoglycans, inhibition of angiogenesis and blood
coagulation homoeostasis (Biochem. J. 2005, 386, 15-27; Arthritis
Res. Ther. 2005, 7, 160-169; Curr. Med. Chem. Anti-Inflammatory
Anti-Allergy Agents 2005, 4, 251-264).
[0005] The mammalian MMP family has been reported to include at
least 20 enzymes (Chem. Rev. 1999, 99, 2735-2776). Collagenase-3
(MMP-13) is among three collagenases that have been identified.
Based on identification of domain structures for individual members
of the MMP family, it has been determined that the catalytic domain
of the MMPs contains two zinc atoms; one of these zinc atoms
performs a catalytic function and is coordinated with three
histidines contained within the conserved amino acid sequence of
the catalytic domain. MMP-13 is over-expressed in rheumatoid
arthritis, osteoarthritis, abdominal aortic aneurysm, breast
carcinoma, squamous cell carcinomas of the head and neck, and
vulvar squamous cell carcinoma. The principal substrates of MMP-13
are fibrillar collagens (types I, II, III) and gelatins,
proteoglycans, cytokines and other components of ECM (extracellular
matrix).
[0006] The activation of the MMPs involves the removal of a
propeptide, which features an unpaired cysteine residue complexed
with the catalytic zinc (II) ion. X-ray crystal structures of the
complex between MMP-3 catalytic domain and TIMP-1 and MMP-14
catalytic domain and TIMP-2 also reveal ligation of the catalytic
zinc (II) ion by the thiol of a cysteine residue. The difficulty in
developing effective MMP inhibiting compounds comprises several
factors, including choice of selective versus broad-spectrum MMP
inhibitors and rendering such compounds bioavailable via an oral
route of administration.
[0007] MMP-3 (stromelysin-1; transin-1) is another member of the
MMP family (FASEB J. 1991, 5, 2145-2154). Human MMP-3 was initially
isolated from cultured human synoviocytes. It is also expressed by
chondrocytes and has been localized in OA cartilage and synovial
tissues (Am. J. Pathol. 1989, 135, 1055-64).
[0008] MMP-3 is produced by basal keratinocytes in a variety of
chronic ulcers. MMP-3 mRNA and Protein were detected in basal
keratinocytes adjacent to but distal from the wound edge in what
probably represents the sites of proliferating epidermis. MMP-3 may
thus prevent the epidermis from healing (J. Clin. Invest. 1994, 94,
79-88).
[0009] MMP-3 serum protein levels are significantly elevated in
patients with early and long-term rheumatoid arthritis (Arthritis
Rheum. 2000, 43, 852-8) and in osteoarthritis patients (Clin.
Orthop. Relat. Res. 2004, 428, 272-85) as well as in other
inflammatory diseases like systemic lupus erythematosis and
ankylosing spondylitis (Rheumatology 2006, 45, 414-20).
[0010] MMP-3 acts on components of the ECM as aggrecan,
fibronectin, gelatin, laminin, elastin, fibrillin and others and on
collagens of type III, IV, V, VII, IX, X (Clin. Orthop. Relat. Res.
2004, 428,272-85). On collagens of type II and IX, MMP-3 exhibits
telopeptidase activity (Arthritis Res. 2001, 3, 107-13; Clin.
Orthop. Relat. Res. 2004, 427, S118-22). MMP-3 can activate other
MMP family members such as MMP-1, MMP-7, MMP-8, MMP-9 and MMP-13
(Ann. Rheum. Dis. 2001, 60 Suppl 3:iii62-7).
[0011] MMP-3 is involved in the regulation of cytokines and
chemokines by releasing TGF.beta.1 from the ECM, activating
TNF.alpha., inactivating IL-1.beta. and releasing IGF (Nat. Rev.
Immunol. 2004, 4, 617-29). A potential role for MMP-3 in the
regulation of macrophage infiltration is based on the ability of
the enzyme to convert active MCP species into antagonistic peptides
(Blood 2002, 100, 1160-7).
[0012] MMP-8 (collagenase-2; neutrophil collagenase; EC 3.4.24.34)
is another member of the MMP family (Biochemistry 1990, 29,
10628-34). Human MMP-8 was initially located in human neutrophils
(Biochemistry 1990, 29, 10620-7). It is also expressed by
macrophages, human mucosal keratinocytes, bronchial epithelial
cells, ginigival fibroblasts, resident synovial and articular
chondrodrocytes mainly in the course of inflammatory conditions
(Cytokine & Growth Factor Rev. 2006, 17, 217-23).
[0013] The activity of MMP-8 is tightly regulated and mostly
limited to the sites of inflammation. MMP-8 is expressed and stored
as an inactive pro-enzyme in the granules of the neutrophils. Only
after the activation of the neutrophils by proinflammatory
mediators, MMP-8 is released and activated to exert its
function.
[0014] MMP-8 plays a key role in the migration of immune cells to
the sites of inflammation. MMP-8 degrades components of the
extracellular matrix (ECM) such as collagen type I, II, III, VII,
X, cartilage aggrecan, laminin-5, nidogen, fibronectin,
proteoglycans and tenascin, thereby facilitating the cells
migration through the ECM barrier. MMP-8 also influences the
biological activity of its substrates. Through proteolytic
processing of the chemokines IL-8, GCP-2, ENA-78, MMP-8 increases
the chemokines ability to activate the infiltrating immune cells.
While MMP-8 inactivates the serine protease inhibitor alpha-1
antitrypsin through its cleavage (Eur. J Biochem. 2003, 270,
3739-49; PloS One 2007, 3, 1-10; Cytokine & Growth Factor Rev.
2006, 17, 217-23).
[0015] MMP-8 has been implicated in the pathogenesis of several
chronic inflammatory diseases characterized by the excessive influx
and activation of neutrophils, including cystic fibrosis (Am. J.
Resprir. Critic. Care Med. 1994, 150, 818-22), rheumatoid arthritis
(Clin. Chim. Acta 1996, 129-43), chronic periodontal disease
(Annals Med. 2006, 38, 306-321) and chronic wounds (J. Surg. Res.
1999, 81, 189-195).
[0016] In osteoarthritis patients, MMP-8 protein expression is
significantly elevated in inflamed human articular cartilage in the
knee and ankle joints (Lab Invest. 1996, 74, 232-40; J. Biol. Chem.
1996, 271, 11023-6).
[0017] The levels of activated MMP-8 in BALF is an indicator of the
disease severity and correlates with the airway obstruction in
patients with asthma, COPD, pulmonary emphysema and bronchiectasis
(Lab Invest. 2002, 82, 1535-45; Am. J. Respir. Crit. Care Med.
1999, 159, 1985-91; Respir. Med. 2005, 99, 703-10; J Pathol. 2001,
194, 232-38).
SUMMARY OF THE INVENTION
[0018] The present invention relates to a new class of heterocyclic
moiety containing pharmaceutical agents which inhibits
metalloproteases. In particular, the present invention provides a
new class of metalloprotease inhibiting compounds that exhibit
potent inhibiting activity towards metalloproteases, in particular
towards MMP-13, MMP-3, MMP-8, and more particulary towards
MMP-13.
[0019] The present invention provides a new classes of heterocyclic
metalloprotease compounds, which is represented by the following
general formula:
##STR00001##
wherein all variables in the preceding Formulas (I) are as defined
hereinbelow.
[0020] The heterocyclic metalloprotease inhibiting compounds of the
present invention may be used in the treatment of metalloprotease
mediated diseases, such as rheumatoid arthritis, osteoarthritis,
abdominal aortic aneurysm, cancer (e.g. but not limited to
melanoma, gastric carcinoma or non-small cell lung carcinoma),
inflammation, atherosclerosis, multiple sclerosis, chronic
obstructive pulmonary disease, ocular diseases (e.g. but not
limited to ocular inflammation, glaucoma, retinopathy of
prematurity, macular degeneration with the wet type preferred and
corneal neovascularization), neurologic diseases, psychiatric
diseases, thrombosis, bacterial infection, Parkinson's disease,
fatigue, tremor, diabetic retinopathy, vascular diseases of the
retina, aging, dementia, cardiomyopathy, renal tubular impairment,
diabetes, psychosis, dyskinesia, pigmentary abnormalities,
deafness, inflammatory and fibrotic syndromes, intestinal bowel
syndrome, allergies, Alzheimers disease, arterial plaque formation,
oncology, periodontal, viral infection, stroke, atherosclerosis,
cardiovascular disease, reperfusion injury, trauma, chemical
exposure or oxidative damage to tissues, chronic wound healing,
wound healing, hemorroid, skin beautifying, pain, inflammatory
pain, bone pain and joint pain, acne, acute alcoholic hepatitis,
acute inflammation, acute pancreatitis, acute respiratory distress
syndrome, adult respiratory disease, airflow obstruction, airway
hyperresponsiveness, alcoholic liver disease, allograft rejections,
angiogenesis, angiogenic ocular disease, arthritis, asthma, atopic
dermatitis, bronchiectasis, bronchiolitis, bronchiolitis
obliterans, burn therapy, cardiac and renal reperfusion injury,
celiac disease, cerebral and cardiac ischemia, CNS tumors, CNS
vasculitis, colds, contusions, cor pulmonae, cough, Crohn's
disease, chronic bronchitis, chronic inflammation, chronic
pancreatitis, chronic sinusitis, crystal induced arthritis, cystic
fibrosis, delayted type hypersensitivity reaction, duodenal ulcers,
dyspnea, early transplantation rejection, emphysema, encephalitis,
endotoxic shock, esophagitis, gastric ulcers, gingivitis,
glomerulonephritis, glossitis, gout, graft vs. host reaction, gram
negative sepsis, granulocytic ehrlichiosis, hepatitis viruses,
herpes, herpes viruses, HIV, hypercapnea, hyperinflation,
hyperoxia-induced inflammation, hypoxia, hypersensitivity,
hypoxemia, inflammatory bowel disease, interstitial pneumonitis,
ischemia reperfusion injury, kaposi's sarcoma associated virus,
liver fibrosis, lupus, malaria, meningitis, multi-organ
dysfunction, necrotizing enterocolitis, osteoporosis, chronic
periodontitis, periodontitis, peritonitis associated with continous
ambulatory peritoneal dialysis (CAPD), pre-term labor,
polymyositis, post surgical trauma, pruritis, psoriasis, psoriatic
arthritis, pulmatory fibrosis, pulmatory hypertension, renal
reperfusion injury, respiratory viruses, restinosis, right
ventricular hypertrophy, sarcoidosis, septic shock, small airway
disease, sprains, strains, subarachnoid hemorrhage, surgical lung
volume reduction, thrombosis, toxic shock syndrome, transplant
reperfusion injury, traumatic brain injury, ulcerative colitis,
vasculitis, ventilation-perfusion mismatching, and wheeze.
[0021] In particular, the heterocyclic metalloprotease inhibiting
compounds of the present invention may be used in the treatment of
MMP-13, MMP-8 and MMP-3 mediated degenerative diseases
characterized by excessive extracellular matrix degradation and/or
remodelling, such as cancer, and chronic inflammatory diseases such
as arthritis, rheumatoid arthritis, osteoarthritis,
atherosclerosis, abdominal aortic aneurysm, inflammation, multiple
sclerosis, parkinsons disease, chronic obstructive pulmonary
disease and pain, such as inflammatory pain, bone pain and joint
pain.
[0022] The present invention also provides heterocyclic
metalloprotease inhibiting compounds that are useful as active
ingredients in pharmaceutical compositions for treatment or
prevention of metalloprotease--especially MMP-13--mediated
diseases. The present invention also contemplates use of such
compounds in pharmaceutical compositions for oral or parenteral
administration, comprising one or more of the heterocyclic
metalloprotease inhibiting compounds disclosed herein.
[0023] The present invention further provides methods of inhibiting
metalloproteases, by administering formulations, including, but not
limited to, oral, rectal, topical, intravenous, parenteral
(including, but not limited to, intramuscular, intravenous), ocular
(ophthalmic), transdermal, inhalative (including, but not limited
to, pulmonary, aerosol inhalation), nasal, sublingual, subcutaneous
or intraarticular formulations, comprising the heterocyclic
metalloprotease inhibiting compounds by standard methods known in
medical practice, for the treatment of diseases or symptoms arising
from or associated with metalloprotease, especially MMP-13,
including prophylactic and therapeutic treatment. Although the most
suitable route in any given case will depend on the nature and
severity of the conditions being treated and on the nature of the
active ingredient. The compounds from this invention are
conveniently presented in unit dosage form and prepared by any of
the methods well-known in the art of pharmacy.
[0024] The heterocyclic metalloprotease inhibiting compounds of the
present invention may be used in combination with a disease
modifying antirheumatic drug, a nonsteroidal anti-inflammatory
drug, a COX-2 selective inhibitor, a COX-1 inhibitor, an
immunosuppressive, a steroid, a biological response modifier, a
viscosupplement, a pain reducing drug or other anti-inflammatory
agents or therapeutics useful for the treatment of chemokines
mediated diseases.
DETAILED DESCRIPTION OF THE INVENTION
[0025] One aspect of the invention relates to a compound having
Formula (I):
##STR00002##
wherein:
[0026] R.sup.4 in each occurrence is independently selected from
R.sup.10, hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl,
heteroaryl, halo, haloalkyl, CF.sub.3,
(C.sub.0-C.sub.6)-alkyl-COR.sup.10,
(C.sub.0-C.sub.6)-alkyl-OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NO.sub.2, (C.sub.O-C.sub.6)-alkyl-CN,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.yOR.sup.10,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.yNR.sup.10OR.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10CONR.sup.11SO.sub.2R.sup.30,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.xR.sup.10,
(C.sub.0-C.sub.6)-alkyl-OC(O)R.sup.10,
(C.sub.0-C.sub.6)-alkyl-OC(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(.dbd.NR.sup.10)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10C(.dbd.NR.sup.11)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10SO.sub.2R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)--NR.sup.11--CN,
O--(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.1R.sup.11,
S(O).sub.x--(C.sub.0-C.sub.6)-alkyl-C(O)OR.sup.10,
S(O).sub.x--(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10--(C.sub.0-C.sub.6)-alkyl-NR.sup.10R-
.sup.11, (C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)R.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)--NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--S(O).sub.yNR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--S(O).sub.yR.sup.10,
O--(C.sub.0-C.sub.6)-alkyl-aryl and
O--(C.sub.0-C.sub.6)-alkyl-heteroaryl,
[0027] wherein each R.sup.4 group is optionally substituted one or
more times, or
[0028] wherein each R.sup.4 group is optionally substituted by one
or more R.sup.14 groups;
[0029] R.sup.8 is selected from R.sup.10 or optionally R.sup.8 and
X.sup.1 when taken together with the nitrogen and sp.sup.2-carbon
atom to which they are attached complete a 5- to 8-membered
unsaturated or partially unsaturated heterocycle optionally
containing additional heteroatoms selected from O, S(O).sub.x, N or
NR.sup.50 and which is optionally substituted one or more
times;
[0030] R.sup.9 in each occurrence is independently selected from
R.sup.10, hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl,
heteroaryl, halo, CHF.sub.2, CF.sub.3, OR.sup.10, SR.sup.10,
COOR.sup.10, CH(CH.sub.3)CO.sub.2H,
(C.sub.0-C.sub.6)-alkyl-COR.sup.10,
(C.sub.0-C.sub.6)-alkyl-OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NO.sub.2, (C.sub.0-C.sub.6)-alkyl-CN,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.yOR.sup.10,
(C.sub.10-C.sub.6)-alkyl-P(O).sub.2OH,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.yNR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10CONR.sup.11SO.sub.2R.sup.30,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.xR.sup.10,
(C.sub.0-C.sub.6)-alkyl-OC(O)R.sup.10,
(C.sub.0-C.sub.6)-alkyl-OC(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(.dbd.NR.sup.10)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10C(.dbd.NR.sup.11)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10C(.dbd.N--CN)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(.dbd.N--CN)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10C(.dbd.N--NO.sub.2)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(.dbd.N--NO.sub.2)NR.sup.10OR.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10SO.sub.2R.sup.11,
C(O)NR.sup.10--(C.sub.0-C.sub.6)-alkyl-heteroaryl,
C(O)NR.sup.10--(C.sub.0-C.sub.6)-alkyl-aryl,
S(O).sub.2NR.sup.10--(C.sub.0-C.sub.6)-alkyl-aryl,
S(O).sub.2NR.sup.10--(C.sub.0-C.sub.6)-alkyl-heteroaryl,
S(O).sub.2NR.sup.10-alkyl,
S(O).sub.2--(C.sub.0-C.sub.6)-alkyl-aryl,
S(O).sub.2--(C.sub.0-C.sub.6)-alkyl-heteroaryl,
(C.sub.0-C.sub.6)-alkyl-C(O)--NR.sup.11--CN,
O--(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
S(O).sub.x--(C.sub.0-C.sub.6)-alkyl-C(O)OR.sup.10,
S(O).sub.x--(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10--(C.sub.0-C.sub.6)-alkyl-NR.sup.10R-
.sup.11, (C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)R.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)--NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--S(O).sub.yNR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10l --S(O).sub.yR.sup.11,
O--(C.sub.0-C.sub.6)-alkyl-aryl and
O--(C.sub.0-C.sub.6)-alkyl-heteroaryl, wherein each R.sup.9 group
is optionally one or more times substituted;
[0031] R.sup.10 and R.sup.11 in each occurrence are independently
selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl,
heterocycloalkyl, fluoroalkyl, heterocycloalkylalkyl, haloalkyl,
alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and
aminoalkyl, wherein alkyl, cycloalkyl, cycloalkylalkyl,
heterocycloalkyl, fluoroalkyl, heterocycloalkylalkyl, alkenyl,
alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and
aminoalkyl are optionally substituted one or more times, or
R.sup.10 and R.sup.11 when taken together with the nitrogen to
which they are attached complete a 3- to 8-membered ring containing
carbon atoms and optionally containing a heteroatom selected from
O, S(O).sub.x, or NR.sup.50 and which is optionally substituted one
or more times;
[0032] R.sup.4 is independently selected from hydrogen, alkyl,
arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclylalkyl and
halo, wherein alkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl
and heterocyclylalkyl are optionally substituted one or more
times;
[0033] R.sup.17 is selected from R.sup.9, alkenyl, alkynyl,
bicycloalkyl, heterobicycloalkyl, spiroalkyl, spiroheteroalkyl,
cycloalkyl fused aryl, heterocycloalkyl fused aryl, cycloalkyl
fused heteroaryl, heterocycloalkyl fused heteroaryl or a bicyclic
or tricyclic fused ring system, wherein at least one ring is
partially saturated, and
[0034] wherein each R.sup.17 group is optionally substituted one or
more times, or
[0035] wherein each R.sup.17 group is optionally substituted one or
more R.sup.9 groups;
[0036] R.sup.30 is selected from alkyl and
(C.sub.0-C.sub.6)-alkyl-aryl, wherein alkyl and aryl are optionally
substituted;
[0037] R.sup.50 in each occurrence is independently selected from
hydrogen, alkyl, aryl, heteroaryl, C(O)R.sup.80 ,
C(O)NR.sup.80R.sup.81, SO.sub.2R.sup.80 and
SO.sub.2NR.sup.80R.sup.81, wherein alkyl, aryl, and heteroaryl are
optionally substituted one or more times;
[0038] R.sup.80 and R.sup.81 in each occurrence are independently
selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl,
heterocycloalkyl, fluoroalkyl, heterocycloalkylalkyl, haloalkyl,
alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and
aminoalkyl, wherein alkyl, cycloalkyl, cycloalkylalkyl,
heterocycloalkyl, fluoroalkyl, heterocycloalkylalkyl, alkenyl,
alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and
aminoalkyl are optionally substituted, or R.sup.80 and R.sup.81
when taken together with the nitrogen to which they are attached
complete a 3- to 8-membered ring containing carbon atoms and
optionally a heteroatom selected from O, S(O).sub.x, NH, and
N(alkyl) and which is optionally substituted one or more times;
[0039] L.sub.c is selected from a single bond or an acyclic,
straight or branched, saturated or unsaturated hydrocarbon chain
having 1 to 10 carbon atoms, optionally containing 1 to 3 groups
independently selected from --S--, --O--, NR.sup.10--,
--NR.sup.10CO--, --CONR.sup.10--, --S(O).sub.x--,
--SO.sub.2NR.sup.10--, --NR.sup.10SO.sub.2--,
NR.sup.10SO.sub.2NR.sup.10--, --NR.sup.10CONR.sup.10--,
--OC(O)NR.sup.10--, --NR.sup.10C(O)O--, which replace single carbon
atoms, which in case that more than two carbon atoms are replaced
are not adjacent, and wherein the hydrocarbon chain is optionally
substituted one or more times;
[0040] L.sub.d is selected from a single bond or a straight or
branched, saturated or unsaturated hydrocarbon chain having 1 to 10
carbon atoms, optionally containing 1 to 3 groups independently
selected from --O--, --NR.sup.10--, --S(O).sub.x--,
--NR.sup.10C(X.sup.1)--, --C(X.sup.1I)NR.sup.10--,
--SO.sub.2NR.sup.10--, --NR.sup.10SO.sub.2--, --O--SO.sub.2--,
--SO.sub.2--O--, --NR.sup.10SO.sub.2NR.sup.10--,
--NR.sup.10C(X.sup.1)NR.sup.10--, --OC(X.sup.1)NR.sup.10--,
--NR.sup.10C(X.sup.1)O--, --OC(X.sup.1)--, --C(X.sup.1)O--,
-Q.sup.2-, --NR.sup.10-Q.sup.2-, -Q.sup.2-NR.sup.10--,
--C(X.sup.1)-Q.sup.2-, -Q.sup.2-C(X.sup.1)--, --O-Q.sup.2-,
--S(O).sub.1-Q.sup.2 and -Q.sup.2-S(O).sub.x-- which replace single
carbon atoms, which in case that more than two carbon atoms are
replaced are not adjacent, and wherein the hydrocarbon chain is
optionally substituted one or more times;
[0041] Q.sup.1 is a 4- to 8-membered ring selected from cycloalkyl,
heterocycloalkyl, bicycloalkyl, heterobicycloalkyl or a 5- or
6-membered ring selected from aryl and heteroaryl, wherein
cycloalkyl, heterocycloalkyl, bicycloalkyl, heterobicycloalkyl,
aryl and heteroaryl are optionally substituted one or more times by
R.sup.4 and optionally a substituent of Q.sup.1 is linked with
L.sub.d to complete a 3- to 8-membered ring containing carbon atoms
and optionally heteroatoms selected from O, S(O).sub.x, --NH, and
--N(alkyl) wherein this new ring is optionally substituted one or
more times;
[0042] Q.sup.2 is independently selected from an aromatic,
partially aromatic or non-aromatic cyclic, bicyclic or multicyclic
system containing 0 to 8 heteroatoms selected from N, O and
S(O).sub.x, which is optionally substituted one or more times with
R.sup.4 and wherein the cycles are optionally spiro fused and
optionally a substituent of Q.sup.2 is linked with L.sub.d to
complete a 3- to 8-membered ring containing carbon atoms and
optionally heteroatoms selected from O, S(O).sub.x, --NH, and
--N(alkyl) wherein this new ring is optionally substituted one or
more times;
[0043] X.sup.1 is independently selected from O, S, NR.sup.10,
NOR.sup.10, N--CN, NCOR.sup.10, N--NO.sub.2, and
N--SO.sub.2R.sup.10;
[0044] Y is selected from O, S(O).sub.x, CR.sup.10R.sup.11, and
NR.sup.10;
[0045] Z.sup.1 is independently selected from C, S, S.dbd.O,
PR.sup.10 and P--OR.sup.10;
[0046] w is independently selected from 0 to 3;
[0047] x is independently selected from 0 to 2;
[0048] y is selected from 1 and 2; and
[0049] N-oxides, pharmaceutically acceptable salts, prodrugs,
formulations, polymorphs, racemic mixtures and stereoisomers
thereof.
[0050] In one embodiment, in conjunction with any above or below
embodiments, Q.sup.2-L.sub.c-R.sup.17 is selected from:
##STR00003## ##STR00004## ##STR00005##
wherein:
[0051] R.sup.5 in each occurrence is independently selected from
hydrogen, alkyl, C(O)NR.sup.10R.sup.11, aryl, arylalkyl,
SO.sub.2NR.sup.10R.sup.11 and C(O)OR.sup.10, wherein alkyl, aryl
and arylalkyl are optionally substituted one or more times;
[0052] E is independently selected from a bond, CR.sup.10R.sup.11,
O, NR.sup.5, S, S.dbd.O, S(.dbd.O).sub.2, C(.dbd.O),
N(R.sup.10)(C.dbd.O), (C.dbd.O)N(R.sup.10),
N(R.sup.10)S(.dbd.O).sub.2, S(.dbd.O).sub.2N(R.sup.10),
C.dbd.N--OR.sup.11, --C(R.sup.10R.sup.11)C(R.sup.10R.sup.11)--,
--CH.sub.2--W.sup.1-- and
##STR00006##
[0053] Q.sup.3 is selected from an aromatic, partially aromatic or
non-aromatic cyclic, bicyclic or multicyclic system containing 0 to
8 heteroatoms selected from N, O and S(O).sub.x, which is
optionally substituted one or more times with R.sup.4;
[0054] Q.sup.4 is selected from an aromatic, partially aromatic or
non-aromatic cyclic, bicyclic or multicyclic system containing 0 to
8 heteroatoms selected from N, O and S(O).sub.x, which is
optionally substituted one or more times with R.sup.4;
[0055] U is independently selected from C(R.sup.5R.sup.10),
NR.sup.5, O, S, S.dbd.O and S(.dbd.O).sub.2;
[0056] W.sup.1 is independently selected from O, NR.sup.5, S,
S.dbd.O, S(.dbd.O).sub.2, N(R.sup.10)(C.dbd.O),
N(R.sup.10)S(.dbd.O).sub.2 and S(.dbd.O).sub.2N(R.sup.10); and
[0057] g and h are independently selected from 0-2.
[0058] In one embodiment, in conjunction with any above or below
embodiments, Q.sup.4 is selected from an aromatic, partially
aromatic or non-aromatic bicyclic or multicyclic system containing
0 to 8 heteroatoms selected from N, O and S(O).sub.x, which is
optionally substituted one or more times with R.sup.4.
[0059] In one embodiment, in conjunction with any above or below
embodiments, the compound is:
##STR00007##
wherein:
[0060] R.sup.8 is selected from R.sup.10 or optionally R.sup.8 and
X.sup.1 when taken together with the nitrogen and sp.sup.2-carbon
atom to which they are attached complete a 5- to 8-membered
unsaturated or partially unsaturated heterocycle optionally
containing additional heteroatoms selected from O, S(O).sub.x, N or
NR.sub.50 and which is optionally substituted one or more
times;
[0061] L, M and T are independently selected from CR.sup.9 and
N;
[0062] X.sup.1 is independently selected from O, S, NR.sup.10,
NOR.sup.10, N--CN, NCOR.sup.10, N--NO.sub.2, and
N--SO.sub.2R.sup.10.
[0063] In one embodiment, in conjunction with any above or below
embodiments, R.sup.4 is substituted 0, 1 or 2 times.
[0064] In one embodiment, in conjunction with any above or below
embodiments, R.sup.4 is substituted by 0, 1 or 2 R.sup.14
groups.
[0065] In one embodiment, in conjunction with any above or below
embodiments, R.sup.6 group is substituted 0, 1 or 2 times.
[0066] In one embodiment, in conjunction with any above or below
embodiments, R.sup.6 group is substituted by 0, 1 or 2 R.sup.14
groups;
[0067] In one embodiment, in conjunction with any above or below
embodiments, R.sup.7 is independently selected from hydrogen,
alkyl, cycloalkyl, halo, R.sup.4 and NR.sup.10R.sup.11, wherein
alkyl and cycloalkyl are optionally substituted one or more times,
or optionally two R.sup.7 groups together at the same carbon atom
form .dbd.O, .dbd.S or.dbd.NR.sup.10;
[0068] In one embodiment, in conjunction with any above or below
embodiments, R.sub.8 is R.sup.10.
[0069] In one embodiment, in conjunction with any above or below
embodiments, R.sup.8 and X.sup.1 when taken together with the
nitrogen and sp.sup.2-carbon atom to which they are attached
complete a 5- to 8-membered unsaturated or partially unsaturated
heterocycle optionally containing additional heteroatoms selected
from O, S(O).sub.x, N or NR.sup.50 and which is substituted 0, 1 or
2 times.
[0070] In one embodiment, in conjunction with any above or below
embodiments, one R.sup.9 is selected from R.sub.10, alkyl,
cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, CHF.sub.2,
CF.sub.3, OR.sup.10, SR.sup.10, COOR.sup.10, CH(CH.sub.3)CO.sub.2H,
(C.sub.0-C.sub.6)-alkyl-COR.sup.10,
(C.sub.0-C.sub.6)-alkyl-OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NO.sub.2, (C.sub.0-C.sub.6)-alkyl-CN,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.yOR.sup.10,
(C.sub.0-C.sub.6)-alkyl-P(O).sub.2OH,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.yNR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10CONR.sup.11SO.sub.2R.sup.30,
(C.sub.0-C.sub.6)-alkyl-S(O).sub.xR.sup.10,
(C.sub.0-C.sub.6)-alkyl-OC(O)R.sup.10,
(C.sub.0-C.sub.6)-alkyl-OC(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(.dbd.NR.sup.10)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10C(.dbd.NR.sup.11)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10C(.dbd.N--CN)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(.dbd.N--CN)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10C(.dbd.N--NO.sub.2)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(.dbd.N--NO.sub.2)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10SO.sub.2R.sup.11,
C(O)NR.sup.10--(C.sub.0-C.sub.6)-alkyl-heteroaryl,
C(O)NR.sup.10--(C.sub.0-C.sub.6)-alkyl-aryl,
S(O).sub.2NR.sup.10--(C.sub.0-C.sub.6)-alkyl-aryl,
S(O).sub.2NR.sup.10--(C.sub.0-C.sub.6)-alkyl-heteroaryl,
S(O).sub.2NR.sup.10-alkyl,
S(O).sub.2--(C.sub.0-C.sub.6)-alkyl-aryl,
S(O).sub.2--(C.sub.0-C.sub.6)-alkyl-heteroaryl,
(C.sub.0-C.sub.6)-alkyl-C(O)--NR.sup.11--CN,
O--(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
S(O).sub.x--(C.sub.0-C.sub.6)-alkyl-C(O)OR.sup.10,
S(O).sub.x--(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-C(O)NR.sup.10--(C.sub.0-C.sub.6)-alkyl-NR.sup.10R-
.sup.11, (C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)R.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)OR.sup.10,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--C(O)--NR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--S(O).sub.yNR.sup.10R.sup.11,
(C.sub.0-C.sub.6)-alkyl-NR.sup.10--S(O).sub.yR.sup.11,
O--(C.sub.0-C.sub.6)-alkyl-aryl and
O--(C.sub.0-C.sub.6)-alkyl-heteroaryl, wherein each R.sup.9 group
is substituted 0, 1 or 2 times; and the remaining R.sup.9 groups
are hydrogen.
[0071] In one embodiment, in conjunction with any above or below
embodiments, R.sup.9 is H.
[0072] In one embodiment, in conjunction with any above or below
embodiments, R.sup.17 is selected from R.sup.9, alkenyl, alkynyl,
bicycloalkyl, heterobicycloalkyl, spiroalkyl, spiroheteroalkyl,
cycloalkyl fused aryl, heterocycloalkyl fused aryl, cycloalkyl
fused heteroaryl, heterocycloalkyl fused heteroaryl or a bicyclic
or tricyclic fused ring system, wherein at least one ring is
partially saturated, and wherein each R.sup.17 group is substituted
0, 1 or 2 times and 0 or 1 R.sup.9 groups.
[0073] In one embodiment, in conjunction with any above or below
embodiments, R.sup.30 is selected from alkyl and
(C.sub.0-C.sub.6)-alkyl-aryl, wherein alkyl and aryl are optionally
substituted 0, 1 or 2 times.
[0074] In one embodiment, in conjunction with any above or below
embodiments, one R.sup.9 is sR.sup.50 in each occurrence is
independently selected from hydrogen, alkyl, aryl, heteroaryl,
C(O)R.sup.80, C(O)NR.sup.80R.sup.8, SO.sub.2R.sup.80 and
SO.sub.2NR.sup.80R.sup.81, wherein alkyl, aryl, and heteroaryl are
substituted 0, 1 or 2 times.
[0075] In one embodiment, in conjunction with any above or below
embodiments, R.sup.80 and R.sup.81 in each occurrence are
independently selected from hydrogen, alkyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl, fluoroalkyl,
heterocycloalkylalkyl, haloalkyl, alkenyl, alkynyl, aryl,
heteroaryl, arylalkyl, heteroarylalkyl and aminoalkyl, wherein
alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, fluoroalkyl,
heterocycloalkylalkyl, alkenyl, alkynyl, aryl, heteroaryl,
arylalkyl, heteroarylalkyl and aminoalkyl are optionally
substituted 0, 1 or 2 times, or R.sup.80 and R.sup.81 when taken
together with the nitrogen to which they are attached complete a 3-
to 8-membered ring containing carbon atoms and optionally a
heteroatom selected from O, S(O).sub.x, NH, and N(alkyl) and which
is optionally substituted 0, 1 or 2 times.
[0076] In one embodiment, in conjunction with any above or below
embodiments, L.sub.c is selected from a single bond or an acyclic,
straight or branched, saturated or unsaturated hydrocarbon chain
having 1 to 10 carbon atoms, optionally containing 1 to 3 groups
independently selected from --S--, --O--, NR.sup.10--,
--NR.sup.10CO--, --CONR.sup.10--, --S(O).sub.x--,
--SO.sub.2NR.sup.10--, --NR.sup.10SO.sub.2--,
NR.sup.10SO.sub.2NR.sup.10--, --NR.sup.10CONR.sup.11--,
--OC(O)NR.sup.10--, --NR.sup.10C(O)O--, which replace single carbon
atoms, which in case that more than two carbon atoms are replaced
are not adjacent, and wherein the hydrocarbon chain is optionally
substituted one or more times;
[0077] In one embodiment, in conjunction with any above or below
embodiments, L.sub.c is absent.
[0078] In one embodiment, in conjunction with any above or below
embodiments, L.sub.c is selected from --CONH-- and --NHCO--.
[0079] In one embodiment, in conjunction with any above or below
embodiments, L.sub.d is selected from a single bond or a straight
or branched, saturated or unsaturated hydrocarbon chain having 1 to
10 carbon atoms, optionally containing 1, 2 or 3 groups
independently selected from --O--, --NR.sup.10--, --S(O).sub.x--,
--NR.sup.10C(X.sup.1)--, --C(X.sup.1)NR.sup.10--,
--SO.sub.2NR.sup.10--, --NR.sup.10 SO.sub.2--, --O--SO.sub.2--,
--SO.sub.2--O--, --NR.sup.10SO.sub.2NR.sup.10--,
--NR.sup.10C(X.sup.1)NR.sup.10--, --OC(X.sup.1)NR.sup.10--,
--NR.sup.10C(X.sup.1)O--, --OC(X.sup.1)--, --C(X.sup.1)O--,
-Q.sup.2-, --NR.sup.10-, -Q.sup.2-, -Q.sup.2-NR.sup.10--,
C(X.sup.1)-Q.sup.2-, -Q.sup.2-C(X.sup.1)--, --O-Q.sup.2-,
--S(O).sub.x-Q.sup.2-, and -Q.sup.2-S(O).sub.x-- which replace
single carbon atoms, which in case that more than two carbon atoms
are replaced are not adjacent, and wherein the hydrocarbon chain is
substituted 0, 1, 2 or 3 times;
[0080] In one embodiment, in conjunction with any above or below
embodiments, L.sub.d is selected from --CH.sub.2NHCO-- and
--CH.sub.2CONH--.
[0081] In one embodiment, in conjunction with any above or below
embodiments, L.sub.d is --CH.sub.2NHCO--.
[0082] In one embodiment, in conjunction with any above or below
embodiments, Q.sup.1 is a 4-, 5-, 6-, 7- or 8-membered ring
selected from cycloalkyl, heterocycloalkyl, bicycloalkyl,
heterobicycloalkyl or a 5- or 6-membered ring selected from aryl
and heteroaryl, wherein cycloalkyl, heterocycloalkyl, bicycloalkyl,
heterobicycloalkyl, aryl and heteroaryl are substituted by 0, 1 or
2 R.sup.4 groups and optionally a substituent of Q.sup.1 is linked
with L.sub.d to complete a 3- to 8-membered ring containing carbon
atoms and optionally heteroatoms selected from O, S(O).sub.x, --NH,
and --N(alkyl) wherein this new ring is optionally substituted one
or more times.
[0083] In one embodiment, in conjunction with any above or below
embodiments, Q.sup.1 is phenyl.
[0084] In one embodiment, in conjunction with any above or below
embodiments, Q.sup.1 is pyridyl.
[0085] In one embodiment, in conjunction with any above or below
embodiments, X.sup.1 is O.
[0086] In one embodiment, in conjunction with any above or below
embodiments, Y is O.
[0087] In one embodiment, in conjunction with any above or below
embodiments, Z.sup.1 is independently selected from C, S, S.dbd.O,
PR.sup.10 and P--OR.sup.10.
[0088] Another aspect of the invention relates to a method of
inhibiting a metalloprotease enzyme, comprising administering a
compound selected from any of the above or below embodiments.
[0089] In another embodiment, in conjunction with any above or
below embodiments, the metalloprotease is selected from MMP-3,
MMP-8, and MMP-13.
[0090] In another embodiment, in conjunction with any above or
below embodiments, the metalloprotease is MMP-13.
[0091] Another aspect of the invention relates to a method of
treating a metalloprotease mediated disease, comprising
administering to a subject in need of such treatment an effective
amount of a compound selected from any of the above or below
embodiments.
[0092] In another embodiment, in conjunction with any above or
below embodiments, the disease is rheumatoid arthritis.
[0093] In another embodiment, in conjunction with any above or
below embodiments, the disease is osteoarthritis.
[0094] In another embodiment, in conjunction with any above or
below embodiments, the disease is inflammation.
[0095] In another embodiment, in conjunction with any above or
below embodiments, the disease is atherosclerosis.
[0096] In another embodiment, in conjunction with any above or
below embodiments, the disease is multiple sclerosis.
[0097] In another embodiment, in conjunction with any above or
below embodiments, the disease is selected from: rheumatoid
arthritis, osteoarthritis, abdominal aortic aneurysm, cancer (e.g.
but not limited to melanoma, gastric carcinoma or non-small cell
lung carcinoma), inflammation, atherosclerosis, chronic obstructive
pulmonary disease, ocular diseases (e.g. but not limited to ocular
inflammation, glaucoma, retinopathy of prematurity, macular
degeneration with the wet type preferred and corneal
neovascularization), neurologic diseases, psychiatric diseases,
thrombosis, bacterial infection, Parkinson's disease, fatigue,
tremor, diabetic retinopathy, vascular diseases of the retina,
aging, dementia, cardiomyopathy, renal tubular impairment,
diabetes, psychosis, dyskinesia, pigmentary abnormalities,
deafness, inflammatory and fibrotic syndromes, intestinal bowel
syndrome, allergies, Alzheimers disease, arterial plaque formation,
oncology, periodontal, viral infection, stroke, atherosclerosis,
cardiovascular disease, reperfusion injury, trauma, chemical
exposure or oxidative damage to tissues, wound healing, hemorroid,
skin beautifying, pain, inflammatory pain, bone pain and joint
pain, acne, acute alcoholic hepatitis, acute inflammation, acute
pancreatitis, acute respiratory distress syndrome, adult
respiratory disease, airflow obstruction, airway
hyperresponsiveness, alcoholic liver disease, allograft rejections,
angiogenesis, angiogenic ocular disease, arthritis, asthma, atopic
dermatitis, bronchiectasis, bronchiolitis, bronchiolitis
obliterans, burn therapy, cardiac and renal reperfusion injury,
celiac disease, cerebral and cardiac ischemia, CNS tumors, CNS
vasculitis, colds, contusions, cor pulmonae, cough, Crohn's
disease, chronic bronchitis, chronic inflammation, chronic
pancreatitis, chronic sinusitis, crystal induced arthritis, cystic
fibrosis, delayted type hypersensitivity reaction, duodenal ulcers,
dyspnea, early transplantation rejection, emphysema, encephalitis,
endotoxic shock, esophagitis, gastric ulcers, gingivitis,
glomerulonephritis, glossitis, gout, graft vs. host reaction, gram
negative sepsis, granulocytic ehrlichiosis, hepatitis viruses,
herpes, herpes viruses, HIV, hypercapnea, hyperinflation,
hyperoxia-induced inflammation, hypoxia, hypersensitivity,
hypoxemia, inflammatory bowel disease, interstitial pneumonitis,
ischemia reperfusion injury, kaposi's sarcoma associated virus,
lupus, malaria, meningitis, multi-organ dysfunction, necrotizing
enterocolitis, osteoporosis, chronic periodontitis, periodontitis,
peritonitis associated with continous ambulatory peritoneal
dialysis (CAPD), pre-term labor, polymyositis, post surgical
trauma, pruritis, psoriasis, psoriatic arthritis, pulmatory
fibrosis, pulmatory hypertension, renal reperfusion injury,
respiratory viruses, restinosis, right ventricular hypertrophy,
sarcoidosis, septic shock, small airway disease, sprains, strains,
subarachnoid hemorrhage, surgical lung volume reduction,
thrombosis, toxic shock syndrome, transplant reperfusion injury,
traumatic brain injury, ulcerative colitis, vasculitis,
ventilation-perfusion mismatching, and wheeze.
[0098] Another aspect of the invention relates to a pharmaceutical
composition comprising:
[0099] A) an effective amount of a compound according to any of the
above or below embodiments;
[0100] B) a pharmaceutically acceptable carrier; and
[0101] C) a drug, agent or therapeutic selected from: (a) a disease
modifying antirheumatic drug; (b) a nonsteroidal anti-inflammatory
drug; (c) a COX-2 selective inhibitor; (d) a COX-1 inhibitor; (e)
an immunosuppressive; (f) a steroid; (g) a biological response
modifier; (h) a viscosupplement; (i) a pain reducing drug; and (j)
a small molecule inhibitor of pro-inflammatory cytokine
production.
[0102] Another aspect of the invention relates to the use of a
compound according to any of the above or below embodiments in the
manufacture of a medicament for treating a metalloprotease mediated
disease.
[0103] Another aspect of the invention relates to the use of a
compound according to any of the above or below embodiments in
conjunction with a a drug, agent or therapeutic selected from: (a)
a disease modifying antirheumatic drug; (b) a nonsteroidal
anti-inflammatory drug; (c) a COX-2 selective inhibitor; (d) a
COX-1 inhibitor; (e) an immunosuppressive; (f) a steroid; (g) a
biological response modifier; (h) a viscosupplement; (i) a pain
reducing drug; and (j) a small molecule inhibitor of
pro-inflammatory cytokine production, in the manufacture of a
medicament for treating a metalloprotease mediated disease.
[0104] The terms "alkyl" or "alk", as used herein alone or as part
of another group, denote optionally substituted, straight and
branched chain saturated hydrocarbon groups, preferably having 1 to
10 carbons in the normal chain, most preferably lower alkyl groups.
Exemplary unsubstituted such groups include methyl, ethyl, propyl,
isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl,
heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl,
decyl, undecyl, dodecyl and the like. Exemplary substituents may
include, but are not limited to, one or more of the following
groups: halo, alkoxy, alkylthio, alkenyl, alkynyl, aryl (e.g., to
form a benzyl group), cycloalkyl, cycloalkenyl, hydroxy or
protected hydroxy, carboxyl (--COOH), alkyloxycarbonyl,
alkylcarbonyloxy, alkylcarbonyl, carbamoyl (NH.sub.2--CO--),
substituted carbamoyl ((R.sup.10)(R.sup.11)N--CO-- wherein R.sup.10
or R.sup.11 are as defined below, except that at least one of
R.sup.10 or R.sup.11 is not hydrogen), amino, heterocyclo, mono- or
dialkylamino, or thiol (--SH).
[0105] The terms "lower alk" or "lower alky" as used herein, denote
such optionally substituted groups as described above for alkyl
having 1 to 4 carbon atoms in the normal chain.
[0106] The term "alkoxy" denotes an alkyl group as described above
bonded through an oxygen linkage (--O--).
[0107] The term "alkenyl", as used herein alone or as part of
another group, denotes optionally substituted, straight and
branched chain hydrocarbon groups containing at least one carbon to
carbon double bond in the chain, and preferably having 2 to 10
carbons in the normal chain. Exemplary unsubstituted such groups
include ethenyl, propenyl, isobutenyl, butenyl, pentenyl, hexenyl,
heptenyl, octenyl, nonenyl, decenyl, and the like. Exemplary
substituents may include, but are not limited to, one or more of
the following groups: halo, alkoxy, alkylthio, alkyl, alkynyl,
aryl, cycloalkyl, cycloalkenyl, hydroxy or protected hydroxy,
carboxyl (--COOH), alkyloxycarbonyl, alkylcarbonyloxy,
alkylcarbonyl, carbamoyl (NH.sub.2--CO--), substituted carbamoyl
((R.sup.10)(R.sup.11)N--CO-- wherein R.sup.10 or R.sup.11 are as
defined below, except that at least one of R.sup.10 or R.sup.11 is
not hydrogen), amino, heterocyclo, mono- or dialkylamino, or thiol
(--SH).
[0108] The term "alkynyl", as used herein alone or as part of
another group, denotes optionally substituted, straight and
branched chain hydrocarbon groups containing at least one carbon to
carbon triple bond in the chain, and preferably having 2 to 10
carbons in the normal chain. Exemplary unsubstituted such groups
include, but are not limited to, ethynyl, propynyl, butynyl,
pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, and the
like. Exemplary substituents may include, but are not limited to,
one or more of the following groups: halo, alkoxy, alkylthio,
alkyl, alkenyl, aryl, cycloalkyl, cycloalkenyl, hydroxy or
protected hydroxy, carboxyl (--COOH), alkyloxycarbonyl,
alkylcarbonyloxy, alkylcarbonyl, carbamoyl (NH.sub.2--CO--),
substituted carbamoyl ((R.sup.10)(R.sup.11)N--CO-- wherein R.sup.10
or R.sup.11 are as defined below, except that at least one of
R.sup.10 or R.sup.11 is not hydrogen), amino, heterocyclo, mono- or
dialkylamino, or thiol (--SH).
[0109] The term "cycloalkyl", as used herein alone or as part of
another group, denotes optionally substituted, saturated cyclic
hydrocarbon ring systems, desirably containing one ring with 3 to 9
carbons. Exemplary unsubstituted such groups include, but are not
limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, cyclooctyl, cyclodecyl, and cyclododecyl. Exemplary
substituents include, but are not limited to, one or more alkyl
groups as described above, or one or more groups described above as
alkyl substituents.
[0110] The term "bicycloalkyl", as used herein alone or as part of
another group, denotes optionally substituted, saturated cyclic
bridged hydrocarbon ring systems, desirably containing 2 or 3 rings
and 3 to 9 carbons per ring. Exemplary unsubstituted such groups
include, but are not limited to, adamantyl, bicyclo[2.2.2]octane,
bicyclo[2.2.1]heptane and cubane. Exemplary substituents include,
but are not limited to, one or more alkyl groups as described
above, or one or more groups described above as alkyl
substituents.
[0111] The term "spiroalkyl", as used herein alone or as part of
another group, denotes optionally substituted, saturated
hydrocarbon ring systems, wherein two rings of 3 to 9 carbons per
ring are bridged via one carbon atom. Exemplary unsubstituted such
groups include, but are not limited to, spiro[3.5]nonane,
spiro[4.5]decane or spiro[2.5]octane. Exemplary substituents
include, but are not limited to, one or more alkyl groups as
described above, or one or more groups described above as alkyl
substituents.
[0112] The term "spiroheteroalkyl", as used herein alone or as part
of another group, denotes optionally substituted, saturated
hydrocarbon ring systems, wherein two rings of 3 to 9 carbons per
ring are bridged via one carbon atom and at least one carbon atom
is replaced by a heteroatom independently selected from N, O and S.
The nitrogen and sulfur heteroatoms may optionally be oxidized.
Exemplary unsubstituted such groups include, but are not limited
to, 1,3-diaza-spiro[4.5]decane-2,4-dione. Exemplary substituents
include, but are not limited to, one or more alkyl groups as
described above, or one or more groups described above as alkyl
substituents.
[0113] The terms "ar" or "aryl", as used herein alone or as part of
another group, denote optionally substituted, homocyclic aromatic
groups, preferably containing 1 or 2 rings and 6 to 12 ring
carbons. Exemplary unsubstituted such groups include, but are not
limited to, phenyl, biphenyl, and naphthyl. Exemplary substituents
include, but are not limited to, one or more nitro groups, alkyl
groups as described above or groups described above as alkyl
substituents.
[0114] The term "heterocycle" or "heterocyclic system" denotes a
heterocyclyl, heterocyclenyl, or heteroaryl group as described
herein, which contains carbon atoms and from 1 to 4 heteroatoms
independently selected from N, O and S and including any bicyclic
or tricyclic group in which any of the above-defined heterocyclic
rings is fused to one or more heterocycle, aryl or cycloalkyl
groups. The nitrogen and sulfur heteroatoms may optionally be
oxidized. The heterocyclic ring may be attached to its pendant
group at any heteroatom or carbon atom which results in a stable
structure. The heterocyclic rings described herein may be
substituted on carbon or on a nitrogen atom.
[0115] Examples of heterocycles include, but are not limited to,
1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl,
3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl,
6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl,
benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolinyl,
benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl,
benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl,
4aH-carbazolyl, b-carbolinyl, chromanyl, chromenyl, cinnolinyl,
decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl,
dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl,
imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl,
indolinyl, indolizinyl, indolyl, isatinoyl, isobenzofuranyl,
isochromanyl, isoindazolyl, isoindolinyl, isoindolyl,
isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl,
naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl,
1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,
1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinylperimidinyl,
oxindolyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl,
phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl,
phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl,
4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl,
pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole,
pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl,
pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl,
4H-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl,
tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl,
tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl,
1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl,
thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl,
thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl,
1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl.
[0116] Further examples of heterocycles include, but not are not
limited to, "heterobicycloalkyl" groups such as 7-oxa-bicyclo[2.2.1
]heptane, 7-aza-bicyclo[2.2.1]heptane, and
1-aza-bicyclo[2.2.2]octane. "Heterocyclenyl" denotes a non-aromatic
monocyclic or multicyclic hydrocarbon ring system of about 3 to
about 10 atoms, desirably about 4 to about 8 atoms, in which one or
more of the carbon atoms in the ring system is/are hetero
element(s) other than carbon, for example nitrogen, oxygen or
sulfur atoms, and which contains at least one carbon-carbon double
bond or carbon-nitrogen double bond. Ring sizes of rings of the
ring system may include 5 to 6 ring atoms. The designation of the
aza, oxa or thia as a prefix before heterocyclenyl define that at
least a nitrogen, oxygen or sulfur atom is present respectively as
a ring atom. The heterocyclenyl may be optionally substituted by
one or more substituents as defined herein. The nitrogen or sulphur
atom of the heterocyclenyl may also be optionally oxidized to the
corresponding N-oxide, S-oxide or S,S-dioxide. "Heterocyclenyl" as
used herein includes by way of example and not limitation those
described in Paquette, Leo A.; "Principles of Modem Heterocyclic
Chemistry" (W. A. Benjamin, New York, 1968), particularly Chapters
1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A
series of Monographs" (John Wiley & Sons, New York, 1950 to
present), in particular Volumes 13, 14, 16, 19, and 28; and "J. Am.
Chem. Soc.", 82:5566 (1960), the contents all of which are
incorporated by reference herein. Exemplary monocyclic
azaheterocyclenyl groups include, but are not limited to,
1,2,3,4-tetrahydrohydropyridine, 1,2-dihydropyridyl,
1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridine,
1,4,5,6-tetrahydropyrimidine, 2-pyrrolinyl, 3-pyrrolinyl,
2-imidazolinyl, 2-pyrazolinyl, and the like. Exemplary
oxaheterocyclenyl groups include, but are not limited to,
3,4-dihydro-2H-pyran, dihydrofuranyl, and fluorodihydrofuranyl. An
exemplary multicyclic oxaheterocyclenyl group is
7-oxabicyclo[2.2.1]heptenyl.
[0117] "Heterocyclyl,"or "heterocycloalkyl," denotes a non-aromatic
saturated monocyclic or multicyclic ring system of about 3 to about
10 carbon atoms, desirably 4 to 8 carbon atoms, in which one or
more of the carbon atoms in the ring system is/are hetero
element(s) other than carbon, for example nitrogen, oxygen or
sulfur. Ring sizes of rings of the ring system may include 5 to 6
ring atoms. The designation of the aza, oxa or thia as a prefix
before heterocyclyl define that at least a nitrogen, oxygen or
sulfur atom is present respectively as a ring atom. The
heterocyclyl may be optionally substituted by one or more
substituents which may be the same or different, and are as defined
herein. The nitrogen or sulphur atom of the heterocyclyl may also
be optionally oxidized to the corresponding N-oxide, S-oxide or
S,S-dioxide.
[0118] "Heterocyclyl" as used herein includes by way of example and
not limitation those described in Paquette, Leo A.; "Principles of
Modern Heterocyclic Chemistry" (W. A. Benjamin, New York, 1968),
particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of
Heterocyclic Compounds, A series of Monographs" (John Wiley &
Sons, New York, 1950 to present), in particular Volumes 13, 14, 16,
19, and 28; and "J. Am. Chem. Soc.", 82:5566 (1960). Exemplary
monocyclic heterocyclyl rings include, but are not limited to,
piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl,
thiazolidinyl, 1,3-dioxolanyl, 1,4-dioxanyl, tetrahydrofuranyl,
tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
[0119] "Heteroaryl" denotes an aromatic monocyclic or multicyclic
ring system of about 5 to about 10 atoms, in which one or more of
the atoms in the ring system is/are hetero element(s) other than
carbon, for example nitrogen, oxygen or sulfur. Ring sizes of rings
of the ring system include 5 to 6 ring atoms. The "heteroaryl" may
also be substituted by one or more substituents which may be the
same or different, and are as defined herein. The designation of
the aza, oxa or thia as a prefix before heteroaryl define that at
least a nitrogen, oxygen or sulfur atom is present respectively as
a ring atom. A nitrogen atom of a heteroaryl may be optionally
oxidized to the corresponding N-oxide. Heteroaryl as used herein
includes by way of example and not limitation those described in
Paquette, Leo A.; "Principles of Modem Heterocyclic Chemistry" (W.
A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7,
and 9; "The Chemistry of Heterocyclic. Compounds, A series of
Monographs" (John Wiley & Sons, New York, 1950 to present), in
particular Volumes 13, 14, 16, 19, and 28; and "J. Am. Chem. Soc.
", 82:5566 (1960). Exemplary heteroaryl and substituted heteroaryl
groups include, but are not limited to, pyrazinyl, thienyl,
isothiazolyl, oxazolyl, pyrazolyl, furazanyl, pyrrolyl,
1,2,4-thiadiazolyl, pyridazinyl, quinoxalinyl, phthalazinyl,
imidazo[1,2-a]pyridine, imidazo[2,1-b]thiazolyl, benzofurazanyl,
azaindolyl, benzimidazolyl, benzothienyl, thienopyridyl,
thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, benzoazaindole,
1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, benzthiazolyl,
dioxolyl, furanyl, imidazolyl, indolyl, indolizinyl, isoxazolyl,
isoquinolinyl, isothiazolyl, oxadiazolyl, oxazinyl, oxiranyl,
piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyridazinyl,
pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, pyrrolidinyl,
quinazolinyl, quinolinyl, tetrazinyl, tetrazolyl,
1,3,4-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl,
1,2,5-thiadiazolyl, thiatriazolyl, thiazinyl, thiazolyl, thienyl,
5-thioxo-1,2,4-diazolyl, thiomorpholino, thiophenyl, thiopyranyl,
triazolyl and triazolonyl.
[0120] The phrase "fused" means, that the group, mentioned before
"fused" is connected via two adjacent atoms to the ring system
mentioned after "fused" to form a bicyclic system. For example,
"heterocycloalkyl fused aryl" includes, but is not limited to,
2,3-dihydro-benzo[1,4]dioxine, 4H-benzo[1,4]oxazin-3-one,
3H-Benzooxazol-2-one and
3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one.
[0121] The term "amino" denotes the radical --NH.sub.2 wherein one
or both of the hydrogen atoms may be replaced by an optionally
substituted hydrocarbon group. Exemplary amino groups include, but
are not limited to, n-butylamino, tert-butylamino,
methylpropylamino and ethyldimethylamino.
[0122] The term "cycloalkylalkyl" denotes a cycloalkyl-alkyl group
wherein a cycloalkyl as described above is bonded through an alkyl,
as defined above. Cycloalkylalkyl groups may contain a lower alkyl
moiety. Exemplary cycloalkylalkyl groups include, but are not
limited to, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl,
cyclopropylethyl, cyclopentylethyl, cyclohexylpropyl,
cyclopropylpropyl, cyclopentylpropyl, and cyclohexylpropyl.
[0123] The term "arylalkyl" denotes an aryl group as described
above bonded through an alkyl, as defined above.
[0124] The term "heteroarylalkyl" denotes a heteroaryl group as
described above bonded through an alkyl, as defined above.
[0125] The term "heterocyclylalkyl," or "heterocycloalkylalkyl,"
denotes a heterocyclyl group as described above bonded through an
alkyl, as defined above.
[0126] The terms "halogen", "halo", or "hal", as used herein alone
or as part of another group, denote chlorine, bromine, fluorine,
and iodine.
[0127] The term "haloalkyl" denotes a halo group as described above
bonded though an alkyl, as defined above. Fluoroalkyl is an
exemplary group.
[0128] The term "aminoalkyl" denotes an amino group as defined
above bonded through an alkyl, as defined above.
[0129] The phrase "bicyclic fused ring system wherein at least one
ring is partially saturated" denotes an 8- to 13-membered fused
bicyclic ring group in which at least one of the rings is
non-aromatic. The ring group has carbon atoms and optionally 1-4
heteroatoms independently selected from N, O and S. The nitrogen
and sulfur heteroatoms may optionally be oxidized. Illustrative
examples include, but are not limited to, indanyl,
tetrahydronaphthyl, tetrahydroquinolyl and benzocycloheptyl.
[0130] The phrase "tricyclic fused ring system wherein at least one
ring is partially saturated" denotes a 9- to 1 8-membered fused
tricyclic ring group in which at least one of the rings is
non-aromatic. The ring group has carbon atoms and optionally 1-7
heteroatoms independently selected from N, O and S. The nitrogen
and sulfur heteroatoms may optionally be oxidized. Illustrative
examples include, but are not limited to, fluorene,
10,11-dihydro-5H-dibenzo[a,d]cycloheptene and
2,2a,7,7a-tetrahydro-1H-cyclobuta[a]indene.
[0131] The phrase "cyclic" denotes to a saturated, partially
unsaturated or unsaturated ring group with one ring. The ring group
has carbon atoms and optionally 1-10 heteroatoms independently
selected from N, O and S. The nitrogen and sulfur heteroatoms may
optionally be oxidized. Illustrative examples include, but are not
limited to, cyclobutane, cyclohexene, morpholine, tetrahydrofurane,
benzene, thiophene, imidazole.
[0132] The phrase "biyclic" denotes to a saturated, partially
unsaturated or unsaturated ring group with two ring. The ring group
has carbon atoms and optionally 1-10 heteroatoms independently
selected from N, O and S. The nitrogen and sulfur heteroatoms may
optionally be oxidized. The rings may be annulated or otherwise
connected, e.g. via a spiro connectivity. Illustrative examples
include, but are not limited to, indane, tetrahydronaphthalin,
tetrahydroquinoline, benzocycloheptane, and
1,3-diaza-spiro[4.5]decane-2,4-dione.
[0133] The phrase "multicyclic" denotes to a saturated, partially
unsaturated or unsaturated ring group with at least three rings.
The ring group has carbon atoms and optionally 1-10 heteroatoms
independently selected from N, O and S. The nitrogen and sulfur
heteroatoms may optionally be oxidized. The rings may be annulated
or otherwise connected, e.g. via a spiro connectivity. Illustrative
examples include, but are not limited to, fluorene, adamantyl,
bicyclo[2.2.2]octane, bicyclo[2.2.1]heptane, cubane,
10,11-dihydro-5H-dibenzo[a,d]cycloheptene,
2,2a,7,7a-tetrahydro-1H-cyclobuta[a]indene,
5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine,
11-oxa-3,5-diaza-tricyclo[6.2.1.0.sup.2,7]undeca-2(7),3,5-triene,
3,5-diaza-tricyclo[6.2.2.0.sup.2,7]dodeca-2(7),3-dien-6-one.
[0134] The term "pharmaceutically acceptable salts" refers to
derivatives of the disclosed compounds wherein the parent compound
is modified by making acid or base salts thereof. Examples of
pharmaceutically acceptable salts include, but are not limited to,
mineral or organic acid salts of basic residues such as amines;
alkali or organic salts of acidic residues such as carboxylic
acids; and the like. Examples therefore may be, but are not limited
to, sodium, potassium, choline, lysine, arginine or
N-methyl-glucamine salts, and the like.
[0135] The pharmaceutically acceptable salts include the
conventional non-toxic salts or the quaternary ammonium salts of
the parent compound formed, for example, from non-toxic inorganic
or organic acids. For example, such conventional non-toxic salts
include those derived from inorganic acids such as, but not limited
to, hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric,
nitric and the like; and the salts prepared from organic acids such
as, but not limited to, acetic, propionic, succinic, glycolic,
stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic,
hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic,
sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic,
methanesulfonic, ethane disulfonic, oxalic, isethionic, and the
like.
[0136] The pharmaceutically acceptable salts of the present
invention can be synthesized from the parent compound which
contains a basic or acidic moiety by conventional chemical methods.
Generally, such salts can be prepared by reacting the free acid or
base forms of these compounds with a stoichiometric amount of the
appropriate base or acid in water or in an organic solvent, or in a
mixture of the two. Organic solvents include, but are not limited
to, nonaqueous media like ethers, ethyl acetate, ethanol,
isopropanol, or acetonitrile. Lists of suitable salts are found in
Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing
Company, Easton, Pa., 1990, p. 1445, the disclosure of which is
hereby incorporated by reference.
[0137] The phrase "pharmaceutically acceptable" denotes those
compounds, materials, compositions, and/or dosage forms which are,
within the scope of sound medical judgment, suitable for use in
contact with the tissues of human beings and animals without
excessive toxicity, irritation, allergic response, or other problem
or complication commensurate with a reasonable benefit/risk
ratio.
[0138] The phrase "pharmaceutically acceptable carrier" denotes
media generally accepted in the art for the delivery of
biologically active agents to mammals, e.g., humans. Such carriers
are generally formulated according to a number of factors well
within the purview of those of ordinary skill in the art to
determine and account for. These include, without limitation: the
type and nature of the active agent being formulated; the subject
to which the agent-containing composition is to be administered;
the intended route of administration of the composition; and, the
therapeutic indication being targeted. Pharmaceutically acceptable
carriers include both aqueous and non-aqueous liquid media, as well
as a variety of solid and semi-solid dosage forms. Such carriers
can include a number of different ingredients and additives in
addition to the active agent, such additional ingredients being
included in the formulation for a variety of reasons, e.g.,
stabilization of the active agent, well known to those of ordinary
skill in the art. Non-limiting examples of a pharmaceutically
acceptable carrier are hyaluronic acid and salts thereof, and
microspheres (including, but not limited to
poly(D,L)-lactide-co-glycolic acid copolymer (PLGA), poly(L-lactic
acid) (PLA), poly(caprolactone (PCL) and bovine serum albumin
(BSA)). Descriptions of suitable pharmaceutically acceptable
carriers, and factors involved in their selection, are found in a
variety of readily available sources, e.g., Remington's
Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton,
Pa., 1985, the contents of which are incorporated herein by
reference.
[0139] Pharmaceutically acceptable carriers particularly suitable
for use in conjunction with tablets include, for example, inert
diluents, such as celluloses, calcium or sodium carbonate, lactose,
calcium or sodium phosphate; disintegrating agents, such as
croscarmellose sodium, cross-linked povidone, maize starch, or
alginic acid; binding agents, such as povidone, starch, gelatin or
acacia; and lubricating agents, such as magnesium stearate, stearic
acid or talc. Tablets may be uncoated or may be coated by known
techniques including microencapsulation to delay disintegration and
adsorption in the gastrointestinal tract and thereby provide a
sustained action over a longer period. For example, a time delay
material such as glyceryl monostearate or glyceryl distearate alone
or with a wax may be employed.
[0140] Formulations for oral use may be also presented as hard
gelatin capsules where the active ingredient is mixed with an inert
solid diluent, for example celluloses, lactose, calcium phosphate
or kaolin, or as soft gelatin capsules wherein the active
ingredient is mixed with non-aqueous or oil medium, such as
glycerin, propylene glycol, polyethylene glycol, peanut oil, liquid
paraffin or olive oil.
[0141] The compositions of the invention may also be formulated as
suspensions including a compound of the present invention in
admixture with at least one pharmaceutically acceptable excipient
suitable for the manufacture of a suspension. In yet another
embodiment, pharmaceutical compositions of the invention may be
formulated as dispersible powders and granules suitable for
preparation of a suspension by the addition of suitable
excipients.
[0142] Carriers suitable for use in connection with suspensions
include suspending agents, such as sodium carboxymethylcellulose,
methylcellulose, hydroxypropyl methylcelluose, sodium alginate,
polyvinylpyrrolidone, gum tragacanth, gum acacia, dispersing or
wetting agents such as a naturally occurring phosphatide (e.g.,
lecithin), a condensation product of an alkylene oxide with a fatty
acid (e.g., polyoxyethylene stearate), a condensation product of
ethylene oxide with a long chain aliphatic alcohol (e.g.,
heptadecaethyleneoxycethanol), a condensation product of ethylene
oxide with a partial ester derived from a fatty acid and a hexitol
anhydride (e.g., polyoxyethylene sorbitan monooleate); and
thickening agents, such as carbomer, beeswax, hard paraffin or
cetyl alcohol. The suspensions may also contain one or more
preservatives such as acetic acid, methyl and/or n-propyl
p-hydroxy-benzoate; one or more coloring agents; one or more
flavoring agents; and one or more sweetening agents such as sucrose
or saccharin.
[0143] Cyclodextrins may be added as aqueous solubility enhancers.
Preferred cyclodextrins include hydroxypropyl, hydroxyethyl,
glucosyl, maltosyl and maltotriosyl derivatives of .alpha.-,
.beta.-, and .gamma.-cyclodextrin. The amount of solubility
enhancer employed will depend on the amount of the compound of the
present invention in the composition.
[0144] The term "formulation" denotes a product comprising the
active ingredient(s) and the inert ingredient(s) that make up the
carrier, as well as any product which results, directly or
indirectly, from combination, complexation or aggregation of any
two or more of the ingredients, or from dissociation of one or more
of the ingredients, or from other types of reactions or
interactions of one or more of the ingredients. Accordingly, the
pharmaceutical formulations of the present invention encompass any
composition made by admixing a compound of the present invention
and a pharmaceutical carrier.
[0145] The term "N-oxide" denotes compounds that can be obtained in
a known manner by reacting a compound of the present invention
including a nitrogen atom (such as in a pyridyl group) with
hydrogen peroxide or a peracid, such as 3-chloroperoxy-benzoic
acid, in an inert solvent, such as dichloromethane, at a
temperature between about -10.degree. C. to 80.degree. C.,
desirably about 0.degree. C.
[0146] The term "polymorph" denotes a form of a chemical compound
in a particular crystalline arrangement. Certain polymorphs may
exhibit enhanced thermodynamic stability and may be more suitable
than other polymorphic forms for inclusion in pharmaceutical
formulations.
[0147] The compounds of the invention can contain one or more
chiral centers and/or double bonds and, therefore, exist as
stereoisomers, such as double-bond isomers (i.e., geometric
isomers), enantiomers, or diastereomers. According to the
invention, the chemical structures depicted herein, and therefore
the compounds of the invention, encompass all of the corresponding
enantiomers and stereoisomers, that is, both the stereomerically
pure form (e.g., geometrically pure, enantiomerically pure, or
diastereomerically pure) and enantiomeric and stereoisomeric
mixtures.
[0148] The term "racemic mixture" denotes a mixture that is about
50% of one enantiomer and about 50% of the corresponding enantiomer
relative to all chiral centers in the molecule. Thus, the invention
encompasses all enantiomerically-pure, enantiomerically-enriched,
and racemic mixtures of compounds of Formula (I).
[0149] Enantiomeric and stereoisomeric mixtures of compounds of the
invention can be resolved into their component enantiomers or
stereoisomers by well-known methods. Examples include, but are not
limited to, the formation of chiral salts and the use of chiral or
high performance liquid chromatography "HPLC" and the formation and
crystallization of chiral salts. See, e.g., Jacques, J., et al.,
Enantiomers, Racemates and Resolutions (Wiley-Interscience, New
York, 1981); Wilen, S. H., et al., Tetrahedron 33:2725 (1977);
Eliel, E. L., Stereochemistry of Carbon Compounds (McGraw-Hill, NY,
1962); Wilen, S. H., Tables of Resolving Agents and Optical
Resolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press,
Notre Dame, Ind., 1972); Stereochemistry of Organic Compounds,
Ernest L. Eliel, Samuel H. Wilen and Lewis N. Manda (1994 John
Wiley & Sons, Inc.), and Stereoselective Synthesis A Practical
Approach, Mihaly Nogradi (1995 VCH Publishers, Inc., NY, N.Y.).
Enantiomers and stereoisomers can also be obtained from
stereomerically- or enantiomerically-pure intermediates, reagents,
and catalysts by well-known asymmetric synthetic methods.
[0150] "Substituted" is intended to indicate that one or more
hydrogens on the atom indicated in the expression using
"substituted" is replaced with a selection from the indicated
group(s), provided that the indicated atom's normal valency is not
exceeded, and that the substitution results in a stable compound.
When a substituent is keto (i.e., .dbd.O) group, then two hydrogens
on the atom are replaced. Furthermore two hydrogens on the atom can
be relaced to form a thiocarbonyl (i.e., .dbd.S) or
.dbd.N--NO.sub.2, .dbd.N--CN, .dbd.N--H,
.dbd.N--(C.sub.1-C.sub.4)alkyl, .dbd.N--OH,
.dbd.N--O(C.sub.1-C.sub.4)alkyl, .dbd.N--CO(C.sub.1-C.sub.4)alkyl,
and .dbd.N--SO.sub.2(C.sub.1-C.sub.4)alkyl.
[0151] Unless moieties of a compound of the present invention are
defined as being unsubstituted, the moieties of the compound may be
substituted. In addition to any substituents provided above, the
moieties of the compounds of the present invention may be
optionally substituted with one or more groups independently
selected from: [0152] B(OH).sub.2; [0153]
B(O--(C.sub.1-C)alkyl).sub.2; [0154] C.sub.1-C.sub.4 alkyl; [0155]
C.sub.2-C.sub.4 alkenyl; [0156] C.sub.2-C.sub.4 alkynyl; [0157]
CF.sub.3; [0158] halo; [0159] OH; [0160] O--(C.sub.1-C.sub.4
alkyl); [0161] OCH.sub.2F; [0162] OCHF.sub.2; [0163] OCF.sub.3;
[0164] ONO.sub.2; [0165] OC(O)--(C.sub.1-C.sub.4 alkyl); [0166]
OC(O)--(C.sub.1-C.sub.4 alkyl); [0167] OC(O)NH--(C.sub.1-C.sub.4
alkyl); [0168] OC(O)N(C.sub.1-C.sub.4 alkyl).sub.2; [0169]
OC(S)NH--(C.sub.1-C.sub.4 alkyl); [0170] OC(S)N(C.sub.1-C.sub.4
alkyl).sub.2; [0171] SH; [0172] S--(C.sub.1-C.sub.4 alkyl); [0173]
S(O)--(C.sub.1-C.sub.4 alkyl); [0174] S(O).sub.2--(C.sub.1-C.sub.4
alkyl); [0175] SC(O)--(C.sub.1-C.sub.4 alkyl); [0176]
SC(O)O--(C.sub.1-C.sub.4 alkyl); [0177] NH.sub.2; [0178]
N(H)--(C.sub.1-C.sub.4 alkyl); [0179] N(C.sub.1-C.sub.4
alkyl).sub.2; [0180] N(H)C(O)--(C.sub.1-C.sub.4 alkyl); [0181]
N(CH.sub.3)C(O)--(C.sub.1-C.sub.4 alkyl); [0182]
N(H)C(O)--CF.sub.3; [0183] N(CH.sub.3)C(O)--CF.sub.3; [0184]
N(H)C(S)--(C.sub.1-C.sub.4 alkyl); [0185]
N(CH.sub.3)C(S)--(C.sub.1-C.sub.4 alkyl); [0186]
N(H)S(O).sub.2--(C.sub.1-C.sub.4 alkyl); [0187] N(H)C(O)NH.sub.2;
[0188] N(H)C(O)NH--(C.sub.1-C.sub.4 alkyl); [0189]
N(CH.sub.3)C(O)NH--(C.sub.1-C.sub.4 alkyl); [0190]
N(H)C(O)N(C.sub.1-C.sub.4 alkyl).sub.2; [0191]
N(CH.sub.3)C(O)N(C.sub.1-C.sub.4 alkyl).sub.2; [0192]
N(H)S(O).sub.2NH.sub.2); [0193] N(H)S(O).sub.2NH--(C.sub.1-C.sub.4
alkyl); [0194] N(CH.sub.3)S(O).sub.2NH--(C.sub.1-C.sub.4 alkyl);
[0195] N(H)S(O).sub.2N(C.sub.1-C.sub.4 alkyl).sub.2; [0196]
N(CH.sub.3)S(O).sub.2N(C.sub.1-C.sub.4 alkyl).sub.2; [0197]
N(H)C(O)O--(C.sub.1-C.sub.4 alkyl); [0198]
N(CH.sub.3)C(O)O--(C.sub.1-C.sub.4 alkyl); [0199]
N(H)S(O).sub.2O--(C.sub.1-C.sub.4 alkyl); [0200]
N(CH.sub.3)S(O).sub.2O--(C.sub.1-C.sub.4 alkyl); [0201]
N(CH.sub.3)C(S)NH--(C.sub.1-C.sub.4 alkyl); [0202]
N(CH.sub.3)C(S)N(C.sub.1-C.sub.4 alkyl).sub.2; [0203]
N(CH.sub.3)C(S)O--(C.sub.1-C.sub.4 alkyl); [0204] N(H)C(S)NH.sub.2;
[0205] NO.sub.2; [0206] CO.sub.2H; [0207]
CO.sub.2--(C.sub.1-C.sub.4 alkyl); [0208] C(O)N(H)OH; [0209]
C(O)N(CH.sub.3)OH: [0210] C(O)N(CH.sub.3)OH; [0211]
C(O)N(CH.sub.3)O--(C.sub.1-C.sub.4 alkyl); [0212]
C(O)N(H)--(C.sub.1-C.sub.4 alkyl); [0213] C(O)N(C.sub.1-C.sub.4
alkyl).sub.2; [0214] C(S)N(H)--(C.sub.1-C.sub.4 alkyl); [0215]
C(S)N(C.sub.1-C.sub.4 alkyl).sub.2; [0216]
C(NH)N(H)--(C.sub.1-C.sub.4 alkyl); [0217] C(NH)N(C.sub.1-C.sub.4
alkyl).sub.2; [0218] C(NCH.sub.3)N(H)--(C.sub.1-C.sub.4 alkyl);
[0219] C(NCH.sub.3)N(C.sub.1-C.sub.4 alkyl).sub.2; [0220]
C(O)--(C.sub.1-C.sub.4 alkyl); [0221] C(NH)--(C.sub.1-C.sub.4
alkyl); [0222] C(NCH.sub.3)--(C.sub.1-C.sub.4 alkyl); [0223]
C(NOH)--(C.sub.1-C.sub.4 alkyl); [0224]
C(NOCH.sub.3)--(C.sub.1-C.sub.4 alkyl); [0225] CN; [0226] CHO;
[0227] CH.sub.2OH; [0228] CH.sub.2O--(C.sub.1-C.sub.4 alkyl);
[0229] CH.sub.2NH.sub.2; [0230] CH.sub.2N(H)--(C.sub.1-C.sub.4
alkyl); [0231] CH.sub.2N(C.sub.1-C.sub.4 alkyl).sub.2; [0232] aryl;
[0233] heteroaryl; [0234] cycloalkyl; and [0235] heterocyclyl.
[0236] In some cases, a ring substituent may be shown as being
connected to the ring by a bond extending from the center of the
ring. The number of such substituents present on a ring is
indicated in subscript by a number. Moreover, the substituent may
be present on any available ring atom, the available ring atom
being any ring atom which bears a hydrogen which the ring
substituent may replace. For illustrative purposes, if variable
R.sup.X were defined as being:
##STR00008##
this would indicate a cyclohexyl ring bearing five R.sup.X
substituents. The R.sup.X substituents may be bonded to any
available ring atom. For example, among the configurations
encompassed by this are configurations such as:
##STR00009##
[0237] These configurations are illustrative and are not meant to
limit the scope of the invention in any way.
[0238] When cyclic ring systems are illustrated with cyles or
fragment of cycles in the formula, it is meant that the bridge atom
connecting the cyclic ring systems with an the substituent (e.g.
another ring) can be a carbon or nitrogen atom. For illustrative
purposes, if the fragment Q.sup.X were defined as being a ring,
wherein two adjacent atoms are substituted to form an additional
6-membered ring:
##STR00010##
[0239] this would indicate that e.g. the following structures are
possible:
##STR00011##
Biological Activity
[0240] The inhibiting activity towards different metalloproteases
of the heterocyclic metalloprotease inhibiting compounds of the
present invention may be measured using any suitable assay known in
the art. A standard in vitro assay for measuring the
metalloprotease inhibiting activity is described in Examples 1700
to 1704. The heterocyclic metalloprotease inhibiting compounds show
activity towards MMP-3, MMP-8 and/or MMP-13.
[0241] Some heterocyclic metalloprotease inhibiting compounds of
the invention have an MMP-13 inhibition activity (IC.sub.50 MMP-13)
ranging from below 0.1 nM to about 20 .mu.M, and typically, from
about 1 nM to about 1 .mu.M. Heterocyclic metalloprotease
inhibiting compounds of the invention desirably have an MMP
inhibition activity ranging from below 0.2 nM to about 20 nM. Table
1 lists typical examples of heterocyclic metalloprotease inhibiting
compounds of the invention that have an MMP-13 activity lower than
100 nM (Group A) and from 100 nM to 20 .mu.M (Group B).
TABLE-US-00001 TABLE 1 Summary of MMP-13 Activity for Compounds
Group Ex. # A 1/2, 1/4, 1/6, 1/7, 1/9, 1/10, 1/11, 1/12, 1/15,
1/16, 1/17, 1/18, 1/19, 1/25, 1/26, 1/29, 1/32, 1/33, 3 B 1, 1/1,
1/5, 1/8, 1/13, 1/23, 1/24, 1/27, 1/30, 1/34
[0242] Some heterocyclic metalloprotease inhibiting compounds of
the invention have an MMP-8 inhibition activity (IC.sub.50 MMP-8)
ranging from below 100 nM to about 20 .mu.M, and typically, from
about 100 nM to about 2 .mu.M. Heterocyclic metalloprotease
inhibiting compounds of the invention desirably have an MMP
inhibition activity ranging below 100 nM. Table 2 lists typical
examples of heterocyclic metalloprotease inhibiting compounds of
the invention that have an MMP-8 activity lower than 250 nM (Group
A) and from 250 nM to 20 .mu.M (Group B).
TABLE-US-00002 TABLE 2 Summary of MMP-8 Activity for Compounds
Group Ex. # A 1/4, 1/9, 1/12, 1/17, 1/32, 3 B 1/6, 1/7, 1/8, 1/15,
1/16, 1/26
[0243] Some heterocyclic metalloprotease inhibiting compounds of
the invention have an MMP-3 inhibition activity (IC.sub.50 MMP-3)
ranging from below 50 nM to about 20 .mu.M, and typically, from
about 10 nM to about 2 .mu.M. Heterocyclic metalloprotease
inhibiting compounds of the invention desirably have an MMP
inhibition activity ranging below 100 nM. Table 2 lists typical
examples of heterocyclic metalloprotease inhibiting compounds of
the invention that have an MMP-3 activity lower than 250 nM (Group
A) and from 250 nM to 20 .mu.M (Group B).
TABLE-US-00003 TABLE 3 Summary of MMP-3 Activity for Compounds
Group Ex. # A 1/4, 1/9, 1/32 B 1/29
[0244] The synthesis of metalloprotease inhibiting compounds of the
invention and their biological activity assay are described in the
following examples which are not intended to be limiting in any
way.
Schemes
[0245] Provided below are schemes according to which compounds of
the present invention may be prepared. Exemplary amine building
blocks of the following structure
##STR00012##
can be obtained similar as described e.g. in WO2006/083454 and
WO2006/128184, with the following representative amine building
blocks:
##STR00013##
[0246] In some embodiments the compounds of Formula (I) are
synthesized by the general methods shown in Scheme 1 to Scheme
4.
##STR00014##
route A
[0247] An carbonic acid and amino substituted compound (e.g.
4-amino-nicotinic acid) is condensed (e.g. EtOH/reflux) with
chloro-oxo-acetic acid ethyl ester as previously described e.g. in
WO2005/105760 in pyridine to give an oxazine ethyl ester (Scheme
1). This intermediate is then converted into the corresponding
pyrimidine derivative using a suitable reagent (e.g. NH.sub.4OAc,
HOAc, EtOH/80.degree. C.). For example, when ring Q is a pyridine
ring. the compound can be obtained according this route A.
route B
[0248] An ester and amino substituted compound (e.g.
2-amino-benzoic acid ethyl ester) is condensed (e.g. 4N HCl,
dioxane/50.degree. C.) with ethyl cyanoformate as previously
described e.g. in WO2005/105760, to give a 1,3-pyrimidine-4-one
ethyl ester (Scheme 1).
route C
[0249] An carboxamide and amino substituted compound (e.g.
2-amino-benzamide) is condensed with an suitable reagent (e.g
oxalic acid diethyl ester or acetic acid anhydride as describend in
DD272079A1 or chloro-oxo-acetic acid ethyl ester as described in J.
Med. Chem. 1979, 22(5), 505-510) to give a 1,3-pyrimidine-4-one
ethyl ester (Scheme 1).
[0250] In case, where Q in Scheme 1 is a thiophene moiety, these
derivatives can be synthesized via the Gewald reaction (J. prakt.
Chem. 1973, 315, 39-43, Monatsh. Chem. 2001,132, 279-293).
[0251] Representative procedures are provided in the application
U.S. 60/860,195 (Nov. 20, 2006).
##STR00015##
[0252] Saponification (e.g. aqueous LiOH) of the
1,3-pyrimidine-4-one derivative of Scheme 1 above gives the
corresponding bicyclic carboxylic acid (Scheme 2). Activated acid
coupling (e.g. EDCI/HOAt) with R.sup.1R.sup.2NH (e.g.
6-aminomethyl-4H-benzo[1,4]oxazin-3-one) in a suitable solvent
gives the desired amide. The saponification/coupling step can be
combined by stirring the ester with the free amine at elevated
temperature (e.g. 200.degree. C., 15 min) under microwave
irradiation.
[0253] In compounds, where the bridge atom is a nitrogen atom, the
following procedure can be applied (Scheme 3).
##STR00016##
[0254] For example, N-(pyrazol-3-yl) acetamide acetate can be
cyclizised with carbonic acid diethyl ester to
2-methylpyrazolo[1,5a]-s-triazine-4-one (J. Heterocycl. Chem. 1985,
22, 601-634) and further oxidized to the corresponding acid (e.g.
by SeO.sub.2 and then oxone).
[0255] In case where Q.sup.2 of Formula (I) is an optionally
substituted 1,3-pyrimidin-4-one, the building block can be
synthesized according Chem. Pharm. Bull. 1982, 30, 4314-4324
(Scheme 4)
##STR00017##
[0256] In the cyclic moiety of the product in Scheme 1 to Scheme 4,
further functional group manipulation can be applied (e.g. J.
March, Advanced Organic Chemistry, Wiley&Sons), e.g. palladium
catalyzed halogen-cyanide exchange or nucleophilic
substitution.
EXAMPLES AND METHODS
[0257] All reagents and solvents were obtained from commercial
sources and used without further purification. Proton spectra
(.sup.1H-NMR) were recorded on a 400 MHz or a 250 MHz NMR
spectrometer in deuterated solvents. Purification by column
chromatography was performed using silica gel, grade 60, 0.06-0.2
mm (chromatography) or silica gel, grade 60, 0.04-0.063 mm (flash
chromatography) and suitable organic solvents as indicated in
specific examples. Preparative thin layer chromatography was
carried out on silica gel plates with UV detection.
[0258] Preparative Examples are directed to intermediate compounds
useful in preparing the compounds of the present invention.
Preparative Example 1
##STR00018##
[0259] Step A
[0260] If one were to treat 3-aza-spiro[5.5]undecan-9-one (Bioorg.
Med. Chem. Lett. 2001, 11, 1293-1296) with a base, e.g.
K.sub.2CO.sub.3 and methyliodide in dry DMF, one would obtain the
title compound.
Step B
[0261] If one were to treat the title compound from Step A above
with ethylcyanoacetate in acetic acid and ammonium acetate in
toluene under reflux with a dean stark condenser one would obtain
the title compound.
Step C
[0262] If one were to treat the title compound from Step B above
with sulfur and diethylamine (0.1 eq.) in dry methanol at
50.degree. C. overnight one would obtain the title compound.
Step D
[0263] If one were to treat the title compound from Step C similar
as desribed in the Preparative Example 11, Step A one would obtain
the title compound.
Step E
[0264] If one were to treat the title compound from Step D similar
as desribed in the Preparative Example 2, Step C one would obtain
the title compound.
Preparative Example 2
##STR00019##
[0265] Step A
[0266] 5-Amino-3-phenylisoxazole (995 mg) was suspended in dry
pyridine (20 mL) and ethyloxalyl chloride (830 .mu.L) was added
under ice cooling. The ice bath was removed and the mixture was
stirred for 2 d at room temperature and evaporated. The residue was
diluted with ethyl acetate and subsequently washed with 10% aqueous
citric acid and brine, dried and concentrated. The residue was
recrystallized from ethyl acetate/cyclohexane to give the title
compound (969 mg, 60%) as colourless needles. [MH].sup.+=261.
Step B
[0267] The title compound from Step A above (548 mg) and PtO.sub.2
(115 mg) were suspended in EtOH (20 mL) and hydrogenated at
atmospheric pressure for 2 h at 50.degree. C., filtered over celite
and refluxed for further 2 h, evaporated and purified by flash
chromatography (cyclohexane/ethyl acetate 6:4 to 4:6) to afford the
title compound as a colourless solid. [MH].sup.+=245.
Step C
[0268] To a solution of the title compound from Step B above (105
mg) in THF (20 mL) was added 1M aqueous LiOH (1 mL). The resulting
mixture was stirred at room temperature for 2 h, concentrated and
neutralized with 1M aqueous HCl. The residue was filtered off and
used without further purification (46 mg, 50%). [MH].sup.+=217.
Preparative Examples 2/1 to 2/3
[0269] Following a similar procedure as described in the
Preparative Example 2 except using the amine indicated in Table I.1
below, the following compounds were prepared.
TABLE-US-00004 TABLE I.1 Prep. Ex. # amine product yield 2/1
##STR00020## ##STR00021## 24%[MH].sup.+ = 169 2/2 ##STR00022##
##STR00023## n.d.[MH].sup.+ = 231 2/3 ##STR00024## ##STR00025##
39%[MH].sup.+ = 235
Preparative Examples 3/1 to 3/22
[0270] If one were to use the procedure as described in the
Preparative Example 2 except using the amine indicated in Table I.2
below, the following compounds would be obtained.
TABLE-US-00005 TABLE I.2 Prep. Ex. # amine product 3/1 ##STR00026##
##STR00027## 3/2 ##STR00028## ##STR00029## 3/3 ##STR00030##
##STR00031## 3/4 ##STR00032## ##STR00033## 3/5 ##STR00034##
##STR00035## 3/6 ##STR00036## ##STR00037## 3/7 ##STR00038##
##STR00039## 3/8 ##STR00040## ##STR00041## 3/9 ##STR00042##
##STR00043## 3/10 ##STR00044## ##STR00045## 3/11 ##STR00046##
##STR00047## 3/12 ##STR00048## ##STR00049## 3/13 ##STR00050##
##STR00051## 3/14 ##STR00052## ##STR00053## 3/15 ##STR00054##
##STR00055## 3/16 ##STR00056## ##STR00057## 3/17 ##STR00058##
##STR00059## 3/18 ##STR00060## ##STR00061## 3/19 ##STR00062##
##STR00063## 3/20 ##STR00064## ##STR00065## 3/21 ##STR00066##
##STR00067## 3/22 ##STR00068## ##STR00069##
Preparative Example 3
##STR00070##
[0271] Step A
[0272] A suspension of 6-amino-2,3-difluorophenol (1.0 g),
K.sub.2CO.sub.3 (3 g), bromoacetylchloride (750 .mu.L) and a
catalytic amount of TBAI in dry acetonitrile was stirred at reflux
overnight, evaporated and diluted with ethyl acetate, washed with
1N HCl, brine and a saturated solution of sodium hydrogen
carbonate, dried and evaporated to give the title compound (1.1 g,
86%) as a brown solid [MH].sup.+=186.
Step B The title compound of Step A above (1.1 g) was dissolved in
acetic acid and bromine (1 mL) was added. The solution was stirred
at room temperature overnight, then additional bromine (1 mL) was
added and the temperature was elevated to 40.degree. C. for 3 h.
The solution was evaporated and diluted with ethyl acetate, washed
with a aqueous solution of sodium sulfite, brine and a saturated
solution of sodium hydrogen carbonate, dried, absorbed on silica
and purified by flash chromatography (cyclohexane/ethyl acetate 8:2
to 7:3) to give the 5-bromo-isomer (787 mg, 50%) and 6-bromo-isomer
(567 mg, 36%) as off-white solids. [MH].sup.+=264/66.
Preparative Examples 3a to 3b
[0273] Following a similar procedure as described in the
Preparative Example 3, except using the aminoalcohols indicated in
Table I.3 below, the following compounds were prepared.
TABLE-US-00006 TABLE I.3 Prep. Ex. # aminealcohol product yield 3a
##STR00071## ##STR00072## n.d.[MH].sup.+ = 246/48 3b ##STR00073##
##STR00074## 19%[MH].sup.+ = 246/48
Preparative Example 4
##STR00075##
[0274] Step A
[0275] A suspension of the title compound from the Preparative
Example 3, Step B (567 mg) and CuCN (230 mg) in dry
N-methyl-pyrrolidin-2-one (15 mL) was degassed under Argon and
heated under microwave irradiation to 200.degree. C. for 2 h. The
mixture was concentrated, diluted with 1N HCl (100 mL) and
extracted with EtOAc (200 mL). The organic layers were washed with
H.sub.2O (2.times.200 mL) and brine (200 mL), dried (MgSO.sub.4),
filtered, absorbed on silica and purified by flash chromatography
(cyclohexane/ethyl acetate 7:3 to 6:5) to give the title compound
as a colourless solid. [MH].sup.+=211.
Step B
[0276] To an ice cooled solution of the title compound from Step A
above in dry MeOH (20 mL) were added di-tert-butyl dicarbonate (500
mg) and NiCl.sub.2.6H.sub.2O (20 mg), followed by the careful
portionwise addition of NaBH.sub.4 (320 mg). The resulting black
mixture was stirred for 20 min at 0-5.degree. C. (ice bath), then
the ice bath was removed and stirring at room temperature was
continued overnight. Then diethylenetriamine was added and the
mixture was concentrated to dryness. The remaining residue was
suspended in EtOAc, washed subsequently with 10% aqueous citric
acid, saturated aqueous NaHCO.sub.3 and brine, dried (MgSO.sub.4),
filtered, concentrated and purified by chromatography (silica,
cyclohexane/EtOAc 7:3 to 1:1) to afford the title compound as a
colourless solid (317 mg, 47% over two steps). [MNa].sup.+=337.
Step C
[0277] The title compound from the Step B above (317 mg) was
stirred in a 4M solution of HCl in 1,4-dioxane (10 mL) at room
temperature overnight and then concentrated to afford the title
compound (256 mg, quant.) as a colourless solid.
[M-NH.sub.2Cl].sup.+=198, [M-Cl].sup.+=215.
Preparative Examples 4a to 4d
[0278] Following a similar procedure as described in the
Preparative Example 4, Step A except using the educt indicated in
Table I.4 below, the following compounds were prepared.
TABLE-US-00007 TABLE I.4 Prep. Ex. # educt product yield 4a
##STR00076## ##STR00077## n.d.[MH].sup.+= 193 4b ##STR00078##
##STR00079## 93%[MH].sup.+ = 193 4c ##STR00080## ##STR00081##
n.d.[MH].sup.+ = 193 4d ##STR00082## ##STR00083## 55%[MH].sup.+ =
211
Preparative Examples 5a to 5f
[0279] Following a similar procedure as described in the
Preparative Example 4, Step B except using the educt indicated in
Table I.5 below, the following compounds were prepared.
TABLE-US-00008 TABLE I.5 Prep. Ex. # educt product yield 5a
##STR00084## ##STR00085## 32% (3 steps)[MNa].sup.+ = 319 5b
##STR00086## ##STR00087## 56%[MNa].sup.+ = 319 5c ##STR00088##
##STR00089## 28% (2 steps)[MNa].sup.+ = 319 5d ##STR00090##
##STR00091## n.d.[MNa].sup.+ = 325 5e ##STR00092## ##STR00093##
58%[MNa].sup.+ = 301 5f ##STR00094## ##STR00095## 64%[MNa].sup.+ =
337
Preparative Examples 6a to 6h
[0280] Following a similar procedure as described in the
Preparative Example 4, Step C except using the educt indicated in
Table I.6 below, the following compounds were prepared.
TABLE-US-00009 TABLE I.6 Prep. Ex. # educt product yield 6a
##STR00096## ##STR00097## quant.[M - Cl].sup.+ = 197 6b
##STR00098## ##STR00099## quant.[M - Cl].sup.+ = 195 6c
##STR00100## ##STR00101## quant.[M - Cl].sup.+ = 197 6d
##STR00102## ##STR00103## quant.[M - Cl].sup.+ = 197 6e
##STR00104## ##STR00105## 66% (2 steps)[M- Cl].sup.+ = 203 6f
##STR00106## ##STR00107## n.d.[M- Cl].sup.+ = 179 6g ##STR00108##
##STR00109## quant.[M- Cl].sup.+ = 220 6h ##STR00110## ##STR00111##
quant.[M- Cl].sup.+ = 215
Preparative Example 7
##STR00112##
[0281] Step A
[0282] To a solution of the starting material (380 mg) in dry THF
was added Lawesson's reagent (660 mg) and the mixture was stirred
for 4 h and then concentrated. The remaining residue was dissolved
in EtOAc, washed subsequently with 10% aqueous citric acid,
saturated aqueous NaHCO.sub.3 and brine, dried (MgSO.sub.4),
filtered, concentrated and purified by chromatography (silica,
cyclohexane/EtOAc 85:15 to 8:2) to afford the title compound as a
colourless solid (312 mg, 78%). [MNa].sup.+=317.
Preparative Example 7a
[0283] Following a similar procedure as described in the
Preparative Example 7, except using the educt indicated in Table
I.7 below, the following compound was prepared.
TABLE-US-00010 TABLE I.7 Prep. Ex. # Educt product yield 7a
##STR00113## ##STR00114## 87%[MH].sup.+ = 244/46
Preparative Example 8
##STR00115##
[0284] Step A
[0285] To a solution of 4-bromo-2-fluoro-6-nitrophenol (6.91 g) in
dry DMF was added methylbromoacetate (3.3 mL), K.sub.2CO.sub.3 (7.4
g) and catalytic amounts of TBAI at 0.degree. C. and the mixture
was stirred for 2 h, allowing to reach room temperature. The
mixture was concentrated, dissolved in EtOAc, washed subsequently
with 1N HCl, saturated aqueous NaHCO.sub.3 and brine, dried
(MgSO.sub.4), filtered, absorbed on silica and purified by
chromatography (silica, cyclohexane/EtOAc 9:1 to 8:2) to afford the
title compound as a colourless solid (8.2 g, 91%).
[MH].sup.+=308/10.
Step B
[0286] The title compound from Step A above (1.35 g) and tin (1.3
g) in conc. HCl (10 mL) and MeOH (2 mL) were heated to reflux for 2
h. The mixture was cooled, poured on water and the solid was
filtered to give the title compound as a colourless solid (985 mg,
91%). [MH].sup.+=246/48.
Preparative Example 8a
##STR00116##
[0287] Step A
[0288] A solution of title compound the from Preparative Example 7a
above (164 mg) and formylhydrazine (50 mg) in butanol was heated
under microwave irradiation to 160.degree. C. for 3 h, absorbed on
silica and purified by flash chromatography (silica,
CH.sub.2Cl.sub.2/methanol 98:2 to 95:5) to afford the title
compound as a colourless solid (129 mg, 76%). [MH]+=252/54.
Preparative Example 9
##STR00117##
[0289] Step A
[0290] A mixture of the title compound from the Preparative Example
8a (125 mg), Zn(CN).sub.2 (44 mg) and Pd(PPh.sub.3).sub.4 (40 mg)
in dry DMF (10 mL) was degassed and heated at 85.degree. C. under
an argon atmosphere overnight. The mixture was concentrated,
diluted with 1N HCl, sonificated, filtered and washed with water,
few methanol and then pentane to afford the title compound (100 mg,
quant.) as a colourless solid. [MH].sup.+=199.
Preparative Example 9a
[0291] Following a similar procedure as described in the
Preparative Example 9, except using the educt indicated in Table
I.8 below, the following compound was prepared.
TABLE-US-00011 TABLE I.8 Prep. Ex. # educt product yield 9a
##STR00118## ##STR00119## n.d.[MH].sup.+ = 175
Preparative Example 10
##STR00120##
[0292] Step A
[0293] The title compound from the Preparative Example 7 (123 mg)
was treated as described in Monatsh. Chem. 1989, 120, 81-84 to
afford the title compound as a colourless solid (120 mg, 89%).
[MNa].sup.+=342.
Preparative Example 11
##STR00121##
[0294] Step A
[0295] A mixture of
benzyl-4-formyltetrahydro-1(2H)-pyridocarboxylate (750 mg, 3 mmol),
methylvinylketone (270 .mu.L, 3.3 mmol) and sulphuric acid (50
.mu.L) in 5 mL benzene were heated at reflux in presence of a
Dean-Stark. After 4 h, 270 .mu.L of methylvinylketone were added
and the heating was pursued for 18 h. The reaction mixture was
dissolved in dichloromethane and washed with a saturated solution
of NaHCO.sub.3. The organic layer was separated, dried over
MgSO.sub.4, filtered and the volatile components removed under
reduced pressure. A purification by flash chromatography
(cyclohexane/ethyl acetate 7/3) afforded the title product (0.114
g, 12%) as a yellow oil. [MH].sup.+=300.
Step B
[0296] The title compound from Step A above (0.29 g) was placed in
EtOH in presence of Pd/C (10%). The reaction mixture was stirred at
room temperature overnight under an hydrogen atmosphere. The
mixture was filtrated over celite and ethanol was removed under
reduced pressure to afford the hydrogenated double bound product
(0.192 g, 66%). [MH].sup.+=302.
Step C
[0297] The title compound from Step B above (190 mg), ethyl
cyanoacetate (90 .mu.L), acetic acid (25 .mu.L) and ammonium
acetate (10 mg) in toluene (5 mL) were heated to reflux in presence
of a Dean-Stark overnight. After concentration of the mixture, a
purification by chromatography on silica (cyclohexane/EtOAc 8/2)
afforded a yellow oil (142 mg, 57%). [MH].sup.+=397.
Step D
[0298] A mixture of the title compound from Step C above (140 mg)
and sulfur (17 mg) in EtOH (3 mL) were heated at 50.degree. C.
Diethylamine (25 .mu.L) was added slowly and the mixture was
stirred at 50.degree. C. for 3 h. After concentration of the
mixture, a purification by chromatography (cyclohexane/EtOAc 8/2)
afforded a yellow oil (128 mg, 63%). [MH].sup.+=429.
Step E
[0299] The title compound from Step D above (125 mg) was dissolved
in a 4M solution of HCl in 1,4-dioxane (5 mL) and nitriloacetic
acid ethyl ester (0.045 mL) was added. The mixture was stirred at
50.degree. C. for 3 hours, concentrated and purified by extraction
with ethyl acetate from an aqueous solution. The redidue was
purified by flash chromatography (cyclohexane/EtOAc 5/5) to afford
the desired product (101 mg, 72%). [MH].sup.+=482.
Step F
[0300] To a solution of the title compound from Step E above (100
mg) in THF (1 mL) was added 1M aqueous LiOH (0,65 mL). The
resulting mixture was stirred at room temperature 1,5 h,
concentrated and neutralized with 1M aqueous HCl. The residue was
filtered off and used without further purification (89 mg, 95%).
[MH].sup.+=454.
Preparative Example 12
##STR00122##
[0301] Step A
[0302] The starting anhydride (341 mg, 1.92 mmol) was suspended in
MeOH (2 mL) and heated in a microwave at 60.degree. C. for 30 min
with stirring. The reaction mixture was concentrated to produce 381
mg of desired ester acid as a white solid. [M-H].sup.-=209.
Step B
[0303] To a mixture of the acid from step A above (203 mg, 0.966
mmol) and triethyl amine (0.27 mL, 0.20 g, 1.94 mmol) in t-BuOH (2
mL) was added DPPA (0.42 mL, 0.53 g, 1.94 mmol) and the reaction
was heated in microwave at 100.degree. C. for 10 min with stirring.
Typical aqueous workup and chromatography produced 216 mg of the
amino ester. [MH].sup.+=282.
Step C
[0304] A mixture of the product from Step B above (55 mg, 0.195
mmol) and ethyl cyanoformate (58 .mu.L, 58 mg, 0.59 mmol) in 4M HCl
in dioxane (1 mL) and dioxane (2 mL) was heated in microwave at
120.degree. C. for 4 h with stirring. The reaction mixture was
concentrated, and the CH.sub.2Cl.sub.2 washes were combined and
concentrated to give 66 mg of desired ester as a yellow solid.
[MH].sup.+=249.
Preparative Examples 12a to 12c
[0305] If one were to follow a similar procedure as in Preparative
Example 12, but starting with the amino esters listed in the Table
I.9 below, one would obtain the products listed.
TABLE-US-00012 TABLE I.9 Prep. Ex. # amino ester product 12a
##STR00123## ##STR00124## 12b ##STR00125## ##STR00126## 12c
##STR00127## ##STR00128##
Preparative Example 13
##STR00129##
[0306] Step A
[0307] The commercially available compound above (500 mg) was
dissolved in a 4M solution of HCl in 1,4-dioxane (5 mL) and
nitriloacetic acid ethyl ester (0.26 mL) was added. The mixture was
stirred at 50.degree. C. for 3 hours, concentrated and purified by
extraction with ethyl acetate from an aqueous solution to afford
the desired product (590 mg, >99%). [MH].sup.+=337.
Preparative Example 14
##STR00130##
[0308] Step A
[0309] To a solution of the Preparative Example 13 above (50 mg) in
THF (0,5 mL) was added 1M aqueous LiOH (0,45 mL). The resulting
mixture was stirred at room temperature 2 h, concentrated and
neutralized with 1M aqueous HCl. The residue was filtered off and
used without further purification (19 mg, 42%). [MH].sup.+=309.
Example 1
##STR00131##
[0310] Step A
[0311] To a solution of the title compound from Preparative Example
11, Step F above (85 mg), EDCI (72 mg) and HOAt (25 mg) in DMF (3
mL) were added N-methylmorpholine (100 .mu.L) and hydrochloride
salt of the 6-Aminomethyl-4H-benzo[1,4]oxazin-3-one (48 mg). The
mixture was stirred overnight and then concentrated. The remaining
residue was suspended in 10% aqueous citric acid and the residue
was filtered to afford the title compound as an off white solid
(115 mg, >99%). [MH].sup.+=614.
Examples 1/1 to 1/33
[0312] Following a similar procedure as described in the Example 1
except using the amines and acids indicated in Table II.1 below,
the following compounds were prepared. If marked with *, the workup
was accomplished via purification by RP-18-chromatography. If not
otherwise stated, the acid and amine building block is commercially
available or the synthesis is described in the Preparative
Examples.
TABLE-US-00013 TABLE II.1 Ex. # amine, acid product yield 1/1
##STR00132## ##STR00133## ##STR00134## 68%[MH].sup.+ = 377 1/2
##STR00135## ##STR00136## ##STR00137## 14%[MH].sup.+ = 329 1/3
##STR00138## ##STR00139## ##STR00140## n.d.[MH].sup.+ = 391 1/4
##STR00141## ##STR00142## ##STR00143## 77%[MH].sup.+ = 351 1/5
##STR00144## ##STR00145## ##STR00146## 57%[MH].sup.+ = 365 1/6
##STR00147## ##STR00148## ##STR00149## 80%[MH].sup.+ = 365 1/7
##STR00150## ##STR00151## ##STR00152## 76%[MH].sup.+ = 351 1/8
##STR00153## ##STR00154## ##STR00155## 74%[MH].sup.+ = 365 1/9
##STR00156## ##STR00157## ##STR00158## 98%[MH].sup.+ = 371 1/10
##STR00159## ##STR00160## ##STR00161## 53%[MH].sup.+ = 369 1/11
##STR00162## ##STR00163## ##STR00164## 38%[MH].sup.+ = 387 1/12
##STR00165## ##STR00166## ##STR00167## 74%[MH].sup.+ = 403 1/13
##STR00168## ##STR00169## ##STR00170## 78%[MH].sup.+ = 352 1/14
##STR00171## ##STR00172## ##STR00173## 86%[MH].sup.+ = 370 1/15
##STR00174## ##STR00175## ##STR00176## 81%[MH].sup.+ = 386 1/16
##STR00177## ##STR00178## ##STR00179## 62%[MH].sup.+ = 367 1/17
##STR00180## ##STR00181## ##STR00182## 63%[MH].sup.+ = 401 1/18
##STR00183## ##STR00184## ##STR00185## 74%[MH].sup.+ = 375 1/19
##STR00186## ##STR00187## ##STR00188## 70%[MH].sup.+ = 409 1/20
##STR00189## ##STR00190## ##STR00191## 89%[MH].sup.+ = 387 1/21
##STR00192## ##STR00193## ##STR00194## 74%[MH].sup.+ = 421 1/22
##STR00195## ##STR00196## ##STR00197## 79%[MH].sup.+ = 369 1/23
##STR00198## ##STR00199## ##STR00200## 90%[MH].sup.+ = 387 1/24
##STR00201## ##STR00202## ##STR00203## 89%[MH].sup.+ = 403 1/25
##STR00204## ##STR00205## ##STR00206## 73%[MH].sup.+ = 369 1/26
##STR00207## ##STR00208## ##STR00209## 88%[MH].sup.+ = 403 1/27
##STR00210## ##STR00211## ##STR00212## 72%[MH].sup.+ = 387 1/28
##STR00213## ##STR00214## ##STR00215## 95%[MH].sup.+ = 421 1/29
##STR00216## ##STR00217## ##STR00218## n.d.[MH].sup.+ = 393 1/30
##STR00219## ##STR00220## ##STR00221## 92%[MH].sup.+ = 392 1/31
##STR00222## ##STR00223## ##STR00224## 92%[MH].sup.+ = 428 1/32
##STR00225## ##STR00226## ##STR00227## n.d.[MH].sup.+ = 449 1/33
##STR00228## ##STR00229## ##STR00230## 54%[MH].sup.+ = 395 1/34
##STR00231## ##STR00232## ##STR00233## n.d.[MH].sup.+ = 365
Examples 2/2 to 2/46
[0313] If one were to treat the acid as described in the Example 1
except using the amines and acids indicated in Table II.2 below,
the following compounds would be obtained.
TABLE-US-00014 TABLE II.2 Ex. # amine, acid product 2/1
##STR00234## ##STR00235## ##STR00236## 2/2 ##STR00237##
##STR00238## ##STR00239## 2/3 ##STR00240## ##STR00241##
##STR00242## 2/4 ##STR00243## ##STR00244## ##STR00245## 2/5
##STR00246## ##STR00247## ##STR00248## 2/6 ##STR00249##
##STR00250## ##STR00251## 2/7 ##STR00252## ##STR00253##
##STR00254## 2/8 ##STR00255## ##STR00256## ##STR00257## 2/9
##STR00258## ##STR00259## ##STR00260## 2/10 ##STR00261##
##STR00262## ##STR00263## 2/11 ##STR00264## ##STR00265##
##STR00266## 2/12 ##STR00267## ##STR00268## ##STR00269## 2/13
##STR00270## ##STR00271## ##STR00272## 2/14 ##STR00273##
##STR00274## ##STR00275## 2/15 ##STR00276## ##STR00277##
##STR00278## 2/16 ##STR00279## ##STR00280## ##STR00281## 2/17
##STR00282## ##STR00283## ##STR00284## 2/18 ##STR00285##
##STR00286## ##STR00287## 2/19 ##STR00288## ##STR00289##
##STR00290## 2/20 ##STR00291## ##STR00292## ##STR00293## 2/21
##STR00294## ##STR00295## ##STR00296## 2/22 ##STR00297##
##STR00298## ##STR00299## 2/23 ##STR00300## ##STR00301##
##STR00302## 2/24 ##STR00303## ##STR00304## ##STR00305## 2/25
##STR00306## ##STR00307## ##STR00308## 2/26 ##STR00309##
##STR00310## ##STR00311## 2/27 ##STR00312## ##STR00313##
##STR00314## 2/28 ##STR00315## ##STR00316## ##STR00317## 2/29
##STR00318## ##STR00319## ##STR00320## 2/30 ##STR00321##
##STR00322## ##STR00323## 2/31 ##STR00324## ##STR00325##
##STR00326## 2/32 ##STR00327## ##STR00328## ##STR00329## 2/33
##STR00330## ##STR00331## ##STR00332## 2/34 ##STR00333##
##STR00334## ##STR00335## 2/35 ##STR00336## ##STR00337##
##STR00338## 2/36 ##STR00339## ##STR00340## ##STR00341## 2/37
##STR00342## ##STR00343## ##STR00344## 2/38 ##STR00345##
##STR00346## ##STR00347## 2/39 ##STR00348## ##STR00349##
##STR00350## 2/40 ##STR00351## ##STR00352## ##STR00353## 2/41
##STR00354## ##STR00355## ##STR00356## 2/42 ##STR00357##
##STR00358## ##STR00359## 2/43 ##STR00360## ##STR00361##
##STR00362## 2/44 ##STR00363## ##STR00364## ##STR00365## 2/45
##STR00366## ##STR00367## ##STR00368## 2/46 ##STR00369##
##STR00370## ##STR00371##
Example 3
##STR00372##
[0314] Step A
[0315] A mixture of ester from the Preparative Example 13, Step C
(66 mg, 0.27 mmol),
6-(aminomethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one HCl salt (58 mg,
0.27 mmol) and triethyl amine (74 .mu.L, 54 mg, 0.53 mmol) in EtOH
(1.5 mL) was heated in microwave at 160.degree. C. for 1 h with
stirring. The reaction mixture was concentrated and purified by
reverse phase HPLC to produce the desired product.
[MH].sup.+=381
Example 4
##STR00373##
[0316] Step A
[0317] A mixture of (4-oxo-3,4-dihydro-quinazolin-2-yl)-acetic acid
methyl ester (28.8 mg, 0.132 mmol),
6-(aminomethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one HCl salt (34.9 mg,
0.163 mmol), and triethylamine (55 .mu.L, 40 mg, 0.40 mmol) in DMF
(1 ml) was heated in a microwave at 160.degree. C. for 5 min, then
180.degree. C. for 1 h. Typical aqueous workup and purification
provided 7.1 mg of the desired product as a pale yellow solid.
[MH].sup.+=365.
Example 4/1 to 4/3
[0318] If one were to follow a similar procedure as that described
in Examples 3 except using the esters and amines indicated in Table
II.3 below, the following compounds would be obtained.
TABLE-US-00015 TABLE II.3 Ex. # amine, ester product 4/1
##STR00374## ##STR00375## ##STR00376## 4/2 ##STR00377##
##STR00378## ##STR00379## 4/3 ##STR00380## ##STR00381##
##STR00382##
Example 5
##STR00383##
[0319] Step A
[0320] A mixture of
(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carbaldehyde (37 mg) and
2-hydrazino-3H-quinazolin-4-one (36.8 mg) in DMF (1 mL) was stirred
at room temperature overnight, diluted with water and filtered. The
remaining solid was slurried in methanol, filtered, washed with few
ethyl acetate and dried to afford the title compound (44 mg, 63%)
as a yellow solid. [MH].sup.+=336.
Example 6
##STR00384##
[0321] Step A
[0322] A mixture of
(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-sulfonyl chloride (36 mg)
and 2-hydrazino-3H-quinazolin-4-one (29 mg) in pyridine (1 mL) was
stirred at room temperature overnight, evaporated, diluted with 1N
HCl and filtered. The remaining solid washed with water and dried
to afford the title compound (38 mg, 67%) as a brown solid.
[MH].sup.+=388.
Example 1700
Assay for Determining MMP-13 Inhibition
[0323] The typical assay for MMP-13 activity is carried out in
assay buffer comprised of 50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM
CaCl.sub.2 and 0.05% Brij-35. Different concentrations of tested
compounds are prepared in assay buffer in 50 .mu.L aliquots. 10
.mu.L of a 50 nM stock solution of catalytic domain of MMP-13
enzyme (produced by Alantos or commercially available from Invitek
(Berlin), Cat.#30100812) is added to the compound solution. The
mixture of enzyme and compound in assay buffer is thoroughly mixed
and incubated for 10 min at room temperature. Upon the completion
of incubation, the assay is started by addition of 40 .mu.L of a
12.5 .mu.M stock solution of MMP-13 fluorescent substrate
(Calbiochem, Cat. No. 444235). The time-dependent increase in
fluorescence is measured at the 320 nm excitation and 390 nm
emission by automatic plate multireader. The IC.sub.50 values are
calculated from the initial reaction rates.
Example 1701
Assay for Determining MMP-3 Inhibition
[0324] The typical assay for MMP-3 activity is carried out in assay
buffer comprised of 50 mM MES, pH 6.0, 10 mM CaCl.sub.2 and 0.05%
Brij-35. Different concentrations of tested compounds are prepared
in assay buffer in 50 .mu.L aliquots. 10 .mu.L of a 100 nM stock
solution of the catalytic domain of MMP-3 enzyme (Biomol, Cat. No.
SE-1 09) is added to the compound solution. The mixture of enzyme
and compound in assay buffer is thoroughly mixed and incubated for
10 min at room temperature. Upon the completion of incubation, the
assay is started by addition of 40 .mu.L of a 12.5 .mu.M stock
solution of NFF-3 fluorescent substrate (Calbiochem, Cat. No.
480455). The time-dependent increase in fluorescence is measured at
the 330 nm excitation and 390 nm emission by an automatic plate
multireader. The IC.sub.50 values are calculated from the initial
reaction rates.
Example 1702
Assay for Determining MMP-8 Inhibition
[0325] The typical assay for MMP-8 activity is carried out in assay
buffer comprised of 50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM
CaCl.sub.2 and 0.05% Brij-35. Different concentrations of tested
compounds are prepared in assay buffer in 50 .mu.L aliquots. 10
.mu.L of a 50 nM stock solution of activated MMP-8 enzyme
(Calbiochem, Cat. No. 444229) is added to the compound solution.
The mixture of enzyme and compound in assay buffer is thoroughly
mixed and incubated for 10 min at 37.degree. C. Upon the completion
of incubation, the assay is started by addition of 40 .mu.L of a 10
.mu.M stock solution of OmniMMP fluorescent substrate (Biomol, Cat.
No. P-126). The time-dependent increase in fluorescence is measured
at the 320 nm excitation and 390 nm emission by an automatic plate
multireader at 37.degree. C. The IC.sub.50 values are calculated
from the initial reaction rates.
Example 1703
Assay for Determining MMP-12 Inhibition
[0326] The typical assay for MMP-12 activity is carried out in
assay buffer comprised of 50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM
CaCl.sub.2 and 0.05% Brij-35. Different concentrations of tested
compounds are prepared in assay buffer in 50 .mu.L aliquots. 10
.mu.L of a 50 nM stock solution of the catalytic domain of MMP-12
enzyme (Biomol, Cat. No. SE-138) is added to the compound solution.
The mixture of enzyme and compound in assay buffer is thoroughly
mixed and incubated for 10 min at room temperature. Upon the
completion of incubation, the assay is started by addition of 40
.mu.L of a 12.5 .mu.M stock solution of OmniMMP fluorescent
substrate (Biomol, Cat. No. P-126). The time-dependent increase in
fluorescence is measured at the 320 nm excitation and 390 nm
emission by automatic plate multireader at 37.degree. C. The
IC.sub.50 values are calculated from the initial reaction
rates.
Example 1704
Assay for Determining Aggrecanase-1 Inhibition
[0327] The typical assay for aggrecanase-1 activity is carried out
in assay buffer comprised of 50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM
CaCl.sub.2 and 0.05% Brij-35. Different concentrations of tested
compounds are prepared in assay buffer in 50 .mu.L aliquots. 10
.mu.L of a 75 nM stock solution of aggrecanase-1 (Invitek) is added
to the compound solution. The mixture of enzyme and compound in
assay buffer is thoroughly mixed. The reaction is started by
addition of 40 .mu.L of a 250 nM stock solution of aggrecan-IGD
substrate (Invitek) and incubation at 37.degree. C . for exact 15
min. The reaction is stopped by addition of EDTA and the samples
are analysed by using aggrecanase ELISA (Invitek, InviLISA, Cat.
No. 30510111) according to the protocol of the supplier. Shortly:
100 .mu.L of each proteolytic reaction are incubated in a
pre-coated micro plate for 90 min at room temperature. After 3
times washing, antibody-peroxidase conjugate is added for 90 min at
room temperature. After 5 times washing, the plate is incubated
with TMB solution for 3 min at room temperature. The peroxidase
reaction is stopped with sulfurous acid and the absorbance is red
at 450 nm. The IC.sub.50 values are calculated from the absorbance
signal corresponding to residual aggrecanase activity.
* * * * *